
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39227605
69975
10.1038/s41598-024-69975-3
Article
Adult Hodgkin lymphoma incidence trends in the United States from 2000 to 2020
Aslani Armin 1
Morsali Soroush 23
Mousavi Seyed Ehsan drehsanmousavii@gmail.com

14
Choupani Samireh 5
Yekta Zahra 6
Nejadghaderi Seyed Aria ariang20@gmail.com

78
1 https://ror.org/04krpx645 grid.412888.f 0000 0001 2174 8913 Department of Community Medicine, Faculty of Medicine, Social Determinants of Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 grid.412888.f 0000 0001 2174 8913 Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
3 https://ror.org/01n71v551 grid.510410.1 0000 0004 8010 4431 Tabriz USERN Office, Universal Scientific Education and Research Network (USERN), Tabriz, Iran
4 https://ror.org/04krpx645 grid.412888.f 0000 0001 2174 8913 Neurosciences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran
5 grid.412888.f 0000 0001 2174 8913 Tabriz University of Medical Sciences, Tabriz, Iran
6 Calaveras County Department of Health, Calaveras County, CA USA
7 https://ror.org/02kxbqc24 grid.412105.3 0000 0001 2092 9755 HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran
8 https://ror.org/01n71v551 grid.510410.1 0000 0004 8010 4431 Systematic Review and Meta‑analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran
3 9 2024
3 9 2024
2024
14 2050011 6 2024
12 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Hodgkin lymphoma (HL) is a rare malignancy affecting the lymphatic system. Our study examined the incidence rates of adult HL based on sex, race/ethnicity, age, and histological subgroups in the United States (US) from 2000 to 2020. Data for this study were extracted from the Surveillance, Epidemiology, and End Results 22 database. HL patients were identified utilizing the International Classification of Diseases for Oncology version 3 and categorized as classical HL, lymphocyte-rich/mixed cell/lymphocyte depleted, nodular sclerosis, classical HL, not otherwise specified, and nodular lymphocyte-predominant HL. The study reported average annual percent change (AAPC). All estimates were presented as counts and age-standardized incidence rates (ASIRs) per 100,000 individuals. Between 2000 and 2019, a total of 70,924 cases of HL were reported in the US. Classical HL was the predominant subtype (94.27%), and most incident cases were among non-Hispanic Whites (66.92%) and those aged 20–29 years (24.86%). The ASIR per 100,000 population was 3.83 for men and 2.92 for women. Both sexes showed declines in the AAPCs between 2000 and 2019 (− 0.64% [− 0.99, − 0.28] and − 0.40% [− 0.77, − 0.03] for men and women, respectively). There was a significant decrease in ASIRs after COVID-19 among both sexes (percent change: − 7.49% [− 11.58, − 3.40]). Throughout all age groups, men had a higher incidence rate compared to women, except for those aged 20–29 years. Although the overall HL incidence rate was lowered in the study period from 2000 to 2019, a dramatic decrease in ASIRs of HL patients following COVID-19 pandemic was observed.

Keywords

Hodgkin’s lymphoma
Surveillance, Epidemiology and End Result
SEER
Incidence
United States
Epidemiology
Subject terms

Cancer epidemiology
Hodgkin lymphoma
issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Hodgkin lymphoma (HL) is an uncommon monoclonal lymphoid neoplasm with B-cell origin, typically manifested by localized nodal diseases1,2. HL is frequently observed in cervical lymph nodes, and it can be categorized into classical HL (CHL) and nodular lymphocyte-predominant HL (NLPHL)3. These two disease entities exhibit variations in both clinical presentation and pathology. In this regard, CHL represents around 95% of all cases of HLs and is categorized into four subgroups: nodular sclerosis HL (NSHL), lymphocyte-rich HL, mixed cellularity, and lymphocyte-depleted4. HLs are characterized by four key features, which are frequent occurrence in cervical lymph nodes, higher prevalence in young adults, the presence of scattered significant mononuclear Hodgkin and multinucleated cells (Reed-Sternberg) within a background of various non-neoplastic inflammatory cells, and the typical observation of T lymphocytes surrounding the neoplastic cells2,4.

Globally, HL accounted for 0.4% of newly reported cancer cases and 0.2% of cancer-related deaths in 20205. In the United States (US), HL has an estimated incidence rate of 0.26 cases per 100,000 individuals in 20205, making up 10% of all diagnosed lymphomas in the country6. This disease exhibits a bimodal distribution, with a higher incidence observed in young adults and individuals aged 55 years and older7. The prevalence of HL is influenced by factors such as sex, age, geographical location, and various environmental risk factors8. Individuals at a heightened risk for HL encompass males9, adolescents and young adults1, those with a history of Epstein-Barr virus (EBV) infection10, individuals with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)11, those with autoimmune diseases12, cigarette smokers13, and individuals with a family history of HL. Furthermore, research indicates variations in HL incidence based on family size and socioeconomic status1.

The impact of the COVID-19 pandemic on HL was significant, marked by a global decrease in the incidence rate of HL by 7.2%14. The prolonged interval between symptom onset and diagnosis observed during this period is indicative of the pandemic’s impact on HL, potentially leading to a higher proportion of patients presenting with advanced-stage disease15.

Prior studies on HL incidence have either been conducted on a global scale1 or have been limited to specific subtypes of hematological cancers, such as Burkitt lymphoma, which is a subtype of non-HL16. However, a more precise examination of the updated trends in HL incidence is necessary for resource allocation and public health planning. Consequently, our objective was to perform a comprehensive analysis of the Surveillance, Epidemiology, and End Results (SEER) database to report the incidence trends of adult (≥ 20 years old) HL from 2000 to 2020 in the US by age, sex, race/ethnicity, and histological subgroups. Additionally, we explored the impact of the COVID-19 pandemic on the overall incidence trends of HL in adults.

Methods

Data source

The SEER Program functions as a comprehensive, population-based cancer data repository within the US. SEER 22 covers approximately 48% of the US population and furnishes information on patient survival rates and cancer stage at initial diagnosis17. The SEER program collects data on patients' demographic characteristics, initial tumor location, tumor morphology, stage at diagnosis, initial treatment, and ongoing monitoring of vital status17. In this study, the SEER 22 database, accessible since April 2023 and comprising data reported up to November 2022, was utilized to calculate the incidence rates and annual percent changes (APCs) of HL from 2000 to 202018,19. Access to the SEER 22 database was conducted following the SEER Research Data Agreement for 1975–2020 Data20, and cancer statistics were published following the SEER 22 guideline21.

Definitions

Cancer cases are presented in frequencies and percentages, with the incidence rate reported as cases per 100,000 people. The APCs over a specified time period demonstrate variation as a constant proportion of the rate observed in the previous year. The average annual percent changes (AAPCs) represent the mean of multiple APCs during a specific time frame. Patients were classified into three groups: Non-Hispanic White (NHW), Non-Hispanic Black (NHB), and Hispanic. However, due to the limited number of cases, the race and ethnicity groups of American Indian/Alaska Native, Native Hawaiian, and Asian/Pacific Islander were only utilized for calculating parameters related to all races and ethnicities. HL patients were identified using the International Classification of Diseases for Oncology version 3. The morphologies were categorized as follows: 1(a) CHL (codes 9650-9655, 9661-9667), with subtypes 1(a)1 lymphocyte-rich/mixed cell/lymphocyte depleted (codes 9651-9655), 1(a)2 nodular sclerosis (codes 9663-9667), 1(a)3 CHL, not otherwise specified (CHL-NOS) (codes 9650, 9661-9662), and 1(b) NLPHL (code 9659).

Statistical analysis

The study made use of the SEER 22 Research Limited-Field Data with Delay-Adjustment database spanning the years 2000 to 202018, which was obtained from SEER*Stat, version 8.4.1.222. To compute the age-standardized incidence rate (ASIR) of HL with delay adjustments, the study employed the SEER 22 Research Limited-Field Data with Delay-Adjustment database for the period from 2000 to 2020. The modeling reporting delay was meant to accommodate anticipated future data revisions, encompassing additions and deletions23. The adjusted counts and the associated delay model can be utilized to identify current trends in cancer incidence more accurately23. The inclusion criteria for cases were limited to individuals diagnosed with cancer whose age at diagnosis was known. Following this, the delay model was implemented, incorporating adjustment factors for variables such as cancer site, registry, age group, race and ethnicity, and year of diagnosis4,24. Moreover, the SEER 22 Research Limited-Field Data database spanning the years 2000 to 2020 was employed to ascertain the ASIRs of HL subtypes18, which was retrieved from SEER*Stat, version 8.4.1.225. The Tiwari technique was applied to estimate the ASIRs using the 2000 US standard population, along with the corresponding 95% confidence interval (CI)26 using the SEER*Stat version 8.4.1.222.

To estimate the APCs, AAPCs27, joinpoint regression modeling, parallelism test, and coincident test28 for ASIRs29, the Joinpoint Regression Program, version 5.0.230 was used. Recognizing the potential bias introduced by the 2020 incidence data due to COVID-19, it was excluded from Joinpoint trends and only represented in graphs.

To compute the APCs of ASIRs for HL, the best fit of least-squares regression lines on the natural logarithm of the rates, with the year of diagnosis as a regressor variable, was employed. A minimum of two observations between two joinpoints and a minimum of two observations from a joinpoint to either end of the data were set as criteria. The selection of models was guided by the weighted Bayesian Information Criteria approach31. The 95% CIs for the AAPCs were calculated using the empirical quantile method32. The parallelism test was used in pairwise comparisons to assess whether the trends of the two groups exhibited similarity over time28. A pairwise comparison employing the coincidence test was also conducted to ascertain whether the rates of the two groups were identical over time.

Results

Hodgkin lymphoma

Overall incidence

Between 2000 and 2019, there were a total of 70,924 cases of adult HL in the US. CHL was the most commonly reported subtype (94.27%). Most of these cases were identified among NHWs (66.92%) and individuals aged 20–29 years (24.86%). The ASIR per 100,000 population was 3.83 (3.79, 3.87) for men and 2.92 (2.88, 2.95) for women. Both sexes experienced a significant decline in AAPCs between 2000 and 2019 at − 0.64% (− 0.99, − 0.28) and − 0.40% (− 0.77, − 0.03) for men and women, respectively. NHW men had the highest ASIR (4.31 [4.26, 4.37]). Among all races and ethnicities, only NHB women exhibited the most significant increase in ASIRs over the 2000–2019 period, with an AAPC of 0.68% (0.08, 1.32) (Table 1 and Fig. 1A–D).Table 1 Counts and age-standardized rate of Hodgkin lymphoma cancer incidence per 100,000 and average annual percent change from 2000 to 2019 in the United States by age, sex, and race.

All race/ethnicities	
Age group (years)	Men	Women	
Case (%)	Delayed ASIR (95% CI)	AAPC (95% CI)	Case (%)	Delayed ASIR (95% CI)	AAPC (95% CI)	
20+ 	39,149 (55.20)	3.83 (3.79, 3.87)	− 0.64 (− 0.99, − 0.28)	31,775 (44.80)	2.92 (2.88, 2.95)	− 0.4 (− 0.77, − 0.03)	
20–29	8792 (12.40)	4.13 (4.05, 4.22)	− 0.48 (− 1.01, 0.07)	8835 (12.46)	4.32 (4.23, 4.41)	− 0.58 (− 1.04, − 0.08)	
30–39	7663 (10.80)	3.72 (3.64, 3.8)	− 1.11 (− 1.62, − 0.62)	6511 (9.18)	3.16 (3.08, 3.24)	− 0.75 (− 1.22, − 0.3)	
40–49	6673 (9.41)	3.28 (3.2, 3.36)	− 1.23 (− 2.01, − 0.52)	4371 (6.16)	2.11 (2.05, 2.18)	− 0.25 (− 0.96, 0.45)	
50–59	5920 (8.35)	3.26 (3.18, 3.35)	− 0.14 (− 0.6, 0.34)	3527 (4.97)	1.85 (1.79, 1.91)	− 0.39 (− 0.94, 0.19)	
60–69	4669 (6.58)	3.84 (3.73, 3.95)	− 1.22 (− 1.98, − 0.37)	3357 (4.73)	2.48 (2.39, 2.56)	− 0.87 (− 1.5, − 0.19)	
70–79	3598 (5.07)	5.22 (5.05, 5.4)	− 0.06 (− 0.99, 1.21)	3157 (4.45)	3.62 (3.5, 3.75)	− 0.58 (− 2.29, 0.94)	
80+ 	1834 (2.59)	5.11 (4.88, 5.35)	0.67 (− 1.43, 3.17)	2017 (2.84)	3.27 (3.12, 3.41)	− 0.41 (− 2.08, 1.06)	
Hispanic	
Age groups	Men	Women	
Case (%)	Delayed ASIR (95% CI)	AAPC (95% CI)	Case (%)	Delayed ASIR (95% CI)	AAPC (95% CI)	
20+ 	6576 (55.99)	3.58 (3.48, 3.68)	− 0.72 (− 1.18, − 0.21)	5169 (44.01)	2.53 (2.46, 2.61)	0.18 (− 0.97, 1.38)	
20–29	1511 (12.87)	2.45 (2.33, 2.58)	1.75 (0.64, 3.15)	1616 (13.76)	2.91 (2.77, 3.06)	0.35 (− 0.65, 1.44)	
30–39	1371 (11.67)	2.48 (2.35, 2.62)	− 0.5 (− 1.63, 0.68)	1034 (8.80)	1.98 (1.86, 2.11)	0.5 (− 0.51, 1.62)	
40–49	1171 (9.97)	2.68 (2.53, 2.84)	− 1.49 (− 2.85, − 0.05)	664 (5.65)	1.55 (1.44, 1.67)	− 0.2 (− 2.19, 2.09)	
50–59	963 (8.20)	3.32 (3.12, 3.54)	− 0.94 (− 2.26, 0.61)	558 (4.75)	1.84 (1.69, 2)	− 1.8 (− 3.56, 0.2)	
60–69	728 (6.20)	4.78 (4.44, 5.14)	− 1.57 (− 3.14, 0.49)	555 (4.73)	3.13 (2.88, 3.4)	− 0.78 (− 2.54, 1.37)	
70–79	597 (5.08)	8.2 (7.55, 8.89)	− 0.28 (− 1.92, 1.71)	485 (4.13)	4.99 (4.55, 5.45)	0.67 (− 2.26, 4.83)	
80+ 	235 (2.00)	7.19 (6.3, 8.17)	− 1.76 (− 3.51, 0.38)	257 (2.19)	4.77 (4.21, 5.39)	− 1.05 (− 3.11, 1.47)	
NHB	
Age groups	Men	Women	
Case (%)	Delayed ASIR (95% CI)	AAPC (95% CI)	Case (%)	Delayed ASIR (95% CI)	AAPC (95% CI)	
20+ 	4501 (54.30)	4.05 (3.93, 4.18)	0.17 (− 0.58, 0.97)	3788 (45.70)	2.94 (2.84, 3.03)	0.68 (0.08, 1.32)	
20–29	1042 (12.57)	3.96 (3.72, 4.21)	0.09 (− 1.67, 2.03)	1004 (12.11)	3.7 (3.48, 3.94)	− 1.11 (− 2.49, 0.28)	
30–39	1027 (12.39)	4.45 (4.18, 4.73)	− 0.15 (− 1.39, 1.11)	899 (10.85)	3.49 (3.26, 3.72)	1.12 (− 0.11, 2.44)	
40–49	1012 (12.21)	4.47 (4.2, 4.75)	0.22 (− 0.86, 1.31)	678 (8.18)	2.66 (2.46, 2.87)	1.59 (− 0.31, 3.65)	
50–59	782 (9.43)	4.16 (3.88, 4.46)	0.7 (− 0.4, 1.96)	544 (6.56)	2.48 (2.28, 2.7)	1.06 (− 0.03, 2.3)	
60–69	391 (4.72)	3.48 (3.14, 3.84)	0.31 (− 1.97, 3.11)	373 (4.50)	2.59 (2.34, 2.87)	− 1.03 (− 3.29, 3)	
70–79	181 (2.18)	3.34 (2.87, 3.87)	− 0.09 (− 2.07, 2.19)	200 (2.41)	2.44 (2.11, 2.8)	1.78 (− 0.11, 4.13)	
80+ 	66 (0.80)	2.85 (2.2, 3.63)	N/A	90 (1.09)	1.88 (1.51, 2.32)	1.51 (− 8.92, 13.54)	
NHW	
Age groups	Men	Women	
Case (%)	Delayed ASIR (95% CI)	AAPC (95% CI)	Case (%)	Delayed ASIR (95% CI)	AAPC (95% CI)	
20+ 	26,182 (55.16)	4.31 (4.26, 4.37)	− 0.72 (− 1.43, − 0.16)	21,283 (44.84)	3.4 (3.36, 3.45)	− 0.56 (− 1.16, 0.01)	
20–29	5662 (11.93)	5.4 (5.26, 5.54)	− 0.74 (− 1.42, − 0.2)	5624 (11.85)	5.53 (5.39, 5.68)	− 0.56 (− 1.47, 0.18)	
30–39	4870 (10.26)	4.53 (4.4, 4.66)	− 1.09 (− 1.65, − 0.57)	4224 (8.90)	3.99 (3.87, 4.11)	− 1 (− 1.55, − 0.48)	
40–49	4229 (8.91)	3.56 (3.45, 3.67)	− 1 (− 1.54, − 0.5)	2854 (6.01)	2.42 (2.33, 2.51)	− 0.17 (− 1.01, 0.6)	
50–59	3914 (8.25)	3.28 (3.18, 3.39)	− 0.1 (− 0.53, 0.33)	2297 (4.84)	1.88 (1.81, 1.96)	− 0.38 (− 1.06, 0.3)	
60–69	3354 (7.07)	3.91 (3.78, 4.05)	− 1.36 (− 2.3, − 0.34)	2318 (4.88)	2.51 (2.41, 2.61)	− 1.18 (− 2.03, − 0.28)	
70–79	2692 (5.67)	5.25 (5.06, 5.46)	− 0.03 (− 0.67, 0.82)	2359 (4.97)	3.75 (3.6, 3.9)	− 1.11 (− 2.24, 0.01)	
80+ 	1461 (3.08)	5.22 (4.96, 5.5)	0.66 (− 1.8, 3.43)	1607 (3.39)	3.36 (3.19, 3.53)	− 1.15 (− 3.06, 0.64)	
NHW, Non-Hispanic White; NHB, Non-Hispanic Black; ASIR, age-standardized incidence rate; CI, confidence interval; AAPC, average annual percent change.

Figure 1 Delayed age-adjusted incidence rate of adult Hodgkin lymphoma over 2000–2019 and in 2020 in the United States, by cancer subtype (A), race/ethnicity (B), age (C), and sex (D). APC: annual percent change. * Represent p-value less than 0.05.

In the more recent period from 2015 to 2019, the US reported a total of 17,903 cases of HL. Most cases were observed among NHWs (62.33%), and the highest incidence occurred in individuals aged 20–29 years (24.47%). During this period, the ASIRs per 100,000 population was 3.56 (3.49, 3.63) for men and 2.73 (2.67, 2.79) for women. There was a significant decrease in ASIRs over the 2015–2019 period in both men and women, with an AAPC of − 1.27% (− 2.20, − 0.92) and − 1.11% (− 1.75, − 0.80), respectively (Table S1).

The findings of the identical and parallel trends are provided in Tables S2 and S3, respectively.

Men

From 2000 to 2019, 39,149 (55.20%) cases of HL were diagnosed in men. The majority of cases were in individuals aged 20–29 years (62.33%) and NHWs (66.88%). Cases between 70 to 79 years had the highest ASIR among all age groups (5.22 [5.05, 5.40]). Individuals between 40 and 49 years showed the highest decrease from 2000 to 2019 (AAPC: − 1.23% [− 2.01, − 0.52]) (Table 1).

Of all the reported cases, 16.80% were among Hispanic men. The majority of cases fell within the age range of 20–29 years (22.98%). The overall delayed ASIR per 100,000 population was 3.58 (3.48, 3.68), with cases between 70 and 79 years having the highest delayed ASIR at 8.20 (7.55, 8.89). The overall AAPC for this group was − 0.72% (− 1.18, − 0.21). Among age groups, those in the 20–29 age group had a significant increase in ASIR with an AAPC of 1.75% (0.64, 3.15), and individuals in the 40–49 age group had the largest decrease in ASIRs (AAPC: − 1.49% [− 2.85, − 0.05]) (Table 1).

The majority of NHB men cases (45.58%) occurred in individuals aged 20–29 years. The delayed ASIR per 100,000 population was 4.05 (3.93, 4.18), with those aged 40–49 years exhibiting the highest ASIR at 4.47 (4.20, 4.75) (Table 1).

The majority of NHW men fell within the 55–69 years age bracket (21.63%). The overall delayed ASIR per 100,000 population was 4.31 (4.26, 4.37) (Table 1).

Women

A total of 31,775 cases of HL were reported among women in the US during the period 2000–2019. The majority of cases were observed in NHWs (66.89%) and within the age range of 20 to 29 years (27.80%). Cases between 20 and 29 years exhibited the highest delayed ASIR among all age groups (4.32 [4.23, 4.41]). Individuals between 60 and 69 years experienced the largest decrease in ASIRs from 2000 to 2019 (AAPC: − 0.87% [− 1.50, − 0.19]). NHB women were the only group to show a significant increase in ASIR from 2000 to 2019, with an AAPC of 0.68% (0.08, 1.32) (Table 1).

Among all women, 16.27% were Hispanics. Most cases were observed in the age group of 20–29 years (31.26%). The delayed ASIR per 100,000 population in Hispanic women was 2.53 (2.46, 2.61), with individuals between 70 and 79 years had the highest ASIR (4.99 [4.55, 5.45]) (Table 1).

Among women, 11.92% of reported cases were NHBs. The majority of cases (26.50%) were in the age group of 20–29 years. The delayed ASIR per 100,000 population in NHB women was 2.94 (2.84, 3.03). Cases between 30 and 39 years had the highest reported ASIR (3.49 [3.26, 3.72]) (Table 1).

The majority of NHW cases occurred in women aged 20–29 years (26.42%). The delayed ASIR per 100,000 population in NHW women was 3.40 (3.36, 3.45). Individuals between 20 and 29 years had the highest reported ASIR (5.53 [5.39, 5.68]) (Table 1).

Age and sex patterns

There was a decrease in incident cases in both sexes from ages 20–24 to 85+ years old. In contrast to the age groups of 20–29 and > 80, where women had a higher incident cases compared to men, in other age groups, men had a higher incident numbers. Concerning the incidence rates, both sexes experienced a steady decline, reaching the minimum at the age range of 45–49 in men and 50–54 in women. This was followed by an increase, peaking at 80–84 for men and 75–79 in women. Throughout all age groups, men had a higher incidence rate compared to women; however, between 20 and 29, women had a higher incidence rates (Fig. 2).Figure 2 Incident cases and delay-adjusted incidence rate of adult Hodgkin lymphoma in the United States among males and females in each age group.

COVID-19 impacts

There was a significant decrease in the ASIRs of adult HL across all races/ethnicities in both sexes within all age groups (percent change (PC): − 7.49% [− 11.58, − 3.40]) and for males (PC: − 7.22% [− 12.76, − 1.69]) and females (PC: − 7.25% [− 13.39, − 1.11]) from 2019 to 2020 (Table 2).Table 2 Percent change in age-standardized, delay-adjusted incidence rates of adult Hodgkin lymphoma from 2019 to 2020, by race and sex, using the November 2022 data submission.

Races/ethnicities	Sex	2019 Delayed ASIR (95% CI)	2020 Delayed ASIR (95% CI)	PC (95% CI)	
All	Both	2.66 (2.58, 2.74)	2.46 (2.38, 2.54)	− 7.49 (− 11.58, − 3.4)	
Female	2.38 (2.27, 2.49)	2.2 (2.1, 2.31)	− 7.25 (− 13.39, − 1.11)	
Male	2.97 (2.85, 3.09)	2.75 (2.63, 2.87)	− 7.22 (− 12.76, − 1.69)	
Hispanic	Both	2.47 (2.31, 2.65)	2.28 (2.13, 2.45)	− 7.7 (− 16.77, 1.37)	
Female	2.08 (1.87, 2.3)	1.89 (1.69, 2.1)	− 9.17 (− 22.57, 4.23)	
Male	2.91 (2.65, 3.19)	2.73 (2.48, 3.01)	− 6.08 (− 18.64, 6.49)	
NHB	Both	2.85 (2.61, 3.11)	2.49 (2.26, 2.73)	− 12.83 (− 23.93, − 1.74)	
Female	2.47 (2.16, 2.81)	2.32 (2.02, 2.64)	− 6.24 (− 23.58, 11.11)	
Male	3.29 (2.91, 3.7)	2.76 (2.41, 3.15)	− 16.05 (− 30.91, − 1.18)	
NHW	Both	3 (2.88, 3.13)	2.81 (2.69, 2.94)	− 6.26 (− 11.8, − 0.73)	
Female	2.76 (2.6, 2.94)	2.58 (2.41, 2.75)	− 6.73 (− 14.96, 1.51)	
Male	3.26 (3.08, 3.44)	3.08 (2.91, 3.26)	− 5.53 (− 13.01, 1.95)	
NHW, Non-Hispanic White; NHB, Non-Hispanic Black; ASIR, age-standardized incidence rate; CI, confidence interval; PC, percent change.

Classical Hodgkin lymphoma (CHL)

From 2000 to 2019, there were 66,861 CHL cases in all age groups in the US. The majority of cases were men (54.62%), NHWs (67.41%), and between 20 and 29 years (25.38%). The ASIR per 100,000 population was 3.57 (3.53, 3.61) for men and 2.78 (2.75, 2.81) for women. NHW men had the highest ASIR (4.03 [3.98, 4.09]). The AAPCs for men and women were − 1.07% (− 1.43, − 0.69) and − 0.75% (− 1.07, − 0.40), respectively, and NHW men had the largest decrease compared to other groups (AAPC: − 1.14% [− 1.88, − 0.56]) (Table 3, Figs. S1–S3). The details of incidence trends for males and females are provided in Appendix 1.Table 3 Counts and age-standardized rate of classical Hodgkin lymphoma incidence per 100,000 and average annual percent change from 2000 to 2019 in the United States by age, sex, and race.

All race/ethnicities	
Age group (years)	Men	Women	
Case (%)	ASIR (95% CI)	AAPC (95% CI)	Case (%)	ASIR (95% CI)	AAPC (95% CI)	
20+ 	36,522 (54.62)	3.57 (3.53, 3.61)	− 1.07 (− 1.43, − 0.69)	30,339 (45.38)	2.78 (2.75, 2.81)	− 0.75 (− 1.07, − 0.4)	
20–29	8326 (12.45)	3.9 (3.82, 3.99)	− 0.74 (− 1.28, − 0.2)	8646 (12.93)	4.22 (4.13, 4.31)	− 0.76 (− 1.23, − 0.23)	
30–39	7138 (10.68)	3.46 (3.38, 3.54)	− 1.56 (− 2.16, − 1)	6322 (9.46)	3.06 (2.98, 3.14)	− 0.95 (− 1.43, − 0.49)	
40–49	6139 (9.18)	3.01 (2.94, 3.09)	− 1.97 (− 2.79, − 1.28)	4104 (6.14)	1.98 (1.92, 2.04)	− 0.88 (− 1.58, − 0.22)	
50–59	5400 (8.08)	2.97 (2.89, 3.05)	− 0.78 (− 1.35, − 0.18)	3222 (4.82)	1.68 (1.63, 1.74)	− 1.08 (− 1.54, − 0.6)	
60–69	4303 (6.44)	3.53 (3.43, 3.64)	− 1.67 (− 2.28, − 1)	3082 (4.61)	2.27 (2.19, 2.35)	− 1.51 (− 2.17, − 0.79)	
70–79	3429 (5.13)	4.97 (4.8, 5.14)	− 0.38 (− 1.77, 1.13)	2988 (4.47)	3.42 (3.3, 3.55)	− 0.96 (− 2.26, 0.47)	
80+ 	1787 (2.67)	4.97 (4.74, 5.2)	0.6 (− 2.18, 3.78)	1975 (2.95)	3.19 (3.05, 3.34)	− 0.58 (− 2.16, 0.82)	
Hispanic	
Age groups	Men	Women	
Case (%)	ASIR (95% CI)	AAPC (95% CI)	Case (%)	ASIR (95% CI)	AAPC (95% CI)	
20+ 	6255 (55.61)	3.41 (3.31, 3.51)	− 1 (− 1.49, − 0.45)	4992 (44.39)	2.43 (2.36, 2.5)	− 0.05 (− 1.18, 1.16)	
20–29	1427 (12.69)	2.31 (2.19, 2.43)	1.51 (0.07, 3.46)	1593 (14.16)	2.86 (2.72, 3)	0.19 (− 0.82, 1.32)	
30–39	1297 (11.53)	2.34 (2.21, 2.47)	− 0.79 (− 1.97, 0.45)	1009 (8.97)	1.92 (1.81, 2.05)	0.31 (− 0.66, 1.37)	
40–49	1110 (9.87)	2.53 (2.39, 2.69)	− 2 (− 3.57, − 0.35)	620 (5.51)	1.44 (1.33, 1.56)	− 0.75 (− 2.92, 1.73)	
50–59	905 (8.05)	3.11 (2.91, 3.32)	− 1.31 (− 2.99, 0.63)	524 (4.66)	1.72 (1.58, 1.88)	− 2.52 (− 4.23, − 0.63)	
60–69	702 (6.24)	4.59 (4.25, 4.94)	− 1.76 (− 3.19, − 0.06)	525 (4.67)	2.95 (2.7, 3.21)	− 0.97 (− 2.87, 1.33)	
70–79	584 (5.19)	7.98 (7.34, 8.66)	− 0.46 (− 1.89, 1.28)	469 (4.17)	4.8 (4.38, 5.26)	0.63 (− 3.08, 5.98)	
80+ 	230 (2.04)	7.01 (6.13, 7.98)	− 1.32 (− 2.87, 0.59)	252 (2.24)	4.66 (4.1, 5.27)	− 0.86 (− 2.79, 1.5)	
NHB	
Age groups	Men	Women	
Case (%)	ASIR (95% CI)	AAPC (95% CI)	Case (%)	ASIR (95% CI)	AAPC (95% CI)	
20+ 	4003 (54.81)	3.59 (3.47, 3.7)	− 0.68 (− 2.44, 1.16)	3300 (45.19)	2.54 (2.46, 2.63)	− 0.26 (− 0.98, 0.5)	
20–29	960 (13.15)	3.63 (3.4, 3.86)	− 0.56 (− 2.49, 1.54)	940 (12.87)	3.45 (3.23, 3.68)	− 1.61 (− 3.09, − 0.13)	
30–39	921 (12.61)	3.97 (3.72, 4.24)	− 0.95 (− 2.29, 0.38)	802 (10.98)	3.1 (2.89, 3.32)	0.64 (− 0.8, 2.18)	
40–49	882 (12.08)	3.88 (3.63, 4.14)	− 1.05 (− 2.3, 0.15)	559 (7.65)	2.18 (2, 2.37)	− 0.08 (− 1.63, 1.48)	
50–59	679 (9.30)	3.59 (3.33, 3.87)	0 (− 1.21, 1.45)	441 (6.04)	2 (1.82, 2.19)	0.06 (− 1.96, 2.37)	
60–69	335 (4.59)	2.96 (2.65, 3.29)	− 0.38 (− 2.85, 2.62)	302 (4.14)	2.08 (1.85, 2.33)	− 1.03 (− 2.99, 1.22)	
70–79	163 (2.23)	3 (2.55, 3.5)	− 0.67 (− 3.12, 2.12)	170 (2.33)	2.06 (1.76, 2.39)	0.8 (− 1.22, 3.21)	
80+ 	63 (0.86)	2.71 (2.08, 3.47)	N/A	86 (1.18)	1.79 (1.43, 2.21)	0.86 (− 8.76, 11.92)	
NHW	
Age groups	Men	Women	
Case (%)	ASIR (95% CI)	AAPC (95% CI)	Case (%)	ASIR (95% CI)	AAPC (95% CI)	
20+ 	24,498 (54.35)	4.03 (3.98, 4.09)	− 1.14 (− 1.88, − 0.56)	20,576 (45.65)	3.29 (3.25, 3.34)	− 0.81 (− 1.21, − 0.35)	
20–29	5389 (11.96)	5.13 (4.99, 5.27)	− 1.15 (− 1.74, − 0.59)	5532 (12.27)	5.43 (5.28, 5.57)	− 0.69 (− 1.67, 0.08)	
30–39	4546 (10.09)	4.22 (4.1, 4.34)	− 1.56 (− 2.25, − 0.92)	4164 (9.24)	3.92 (3.8, 4.04)	− 1.13 (− 1.67, − 0.61)	
40–49	3911 (8.68)	3.29 (3.19, 3.39)	− 1.65 (− 2.25, − 1.13)	2759 (6.12)	2.33 (2.25, 2.42)	− 0.55 (− 1.38, 0.22)	
50–59	3581 (7.94)	3 (2.9, 3.1)	− 0.74 (− 1.18, − 0.29)	2149 (4.77)	1.76 (1.69, 1.84)	− 0.94 (− 1.57, − 0.32)	
60–69	3085 (6.84)	3.59 (3.46, 3.72)	− 1.83 (− 2.94, − 0.65)	2158 (4.79)	2.33 (2.23, 2.43)	− 1.79 (− 2.56, − 0.99)	
70–79	2561 (5.68)	4.99 (4.8, 5.19)	− 0.36 (− 1.07, 0.75)	2239 (4.97)	3.55 (3.41, 3.7)	− 1.34 (− 3.09, 0.1)	
80+ 	1425 (3.16)	5.08 (4.82, 5.35)	0.49 (− 2.25, 3.54)	1575 (3.49)	3.28 (3.12, 3.45)	− 0.58 (− 2.67, 1.16)	
NHW, non-Hispanic White; NHB, non-Hispanic Black; ASIR, age-standardized incidence rate; CI, confidence interval; AAPC, average annual percent change.

There was a decrease in incident cases of CHL with ageing. Regarding the incidence rates, both sexes experienced a gradual decline, reaching its lowest point in the age range of 45–49 for men and 50–54 for women. Subsequently, there was an increase, peaking at 80–84 for men and 75–79 for women. Across all age groups, men consistently had higher incidence rates than women, except for the 20–29 age range (Fig. S4).

Lymphocyte-rich/mixed cell/lymphocyte-depleted Hodgkin lymphoma (LR/MC/LD HL)

Over 2000–2019, there were a total of 11,188 cases of LR/MC/LD HL in the US across all age groups. The majority of cases were observed in men (62.65%), NHWs (64.48%), and individuals aged 50–59 years (17.05%). The ASIR per 100,000 population was 0.69 (0.67, 0.71) for men and 0.37 (0.36, 0.38) for women. Hispanic men had the highest ASIR compared to other groups at 0.79 (0.74, 0.84). The AAPC for men and women were − 4.20% (− 4.88, − 3.70) and − 3.50 (− 4.31, − 2.79), respectively. Hispanic men experienced the most significant decline from 2000 to 2019 (AAPC: − 4.48% [− 5.88, − 3.10]) (Table 4, Figs. S5–S7). The details of incidence trends for males and females are provided in Appendix 1.Table 4 Counts and age-standardized rate of lymphocyte-rich/mixed cell/lymphocyte depleted Hodgkin cancer incidence per 100,000 and average annual percent change from 2000 to 2019 in the United States, by age, sex, and race.

All race/ethnicities	
Age group (years)	Men	Women	
Case (%)	ASIR (95% CI)	AAPC (95% CI)	Case (%)	ASIR (95% CI)	AAPC (95% CI)	
20+ 	7009 (62.65)	0.69 (0.67, 0.71)	− 4.2 (− 4.88, − 3.7)	4179 (37.35)	0.37 (0.36, 0.38)	− 3.5 (− 4.31, − 2.79)	
20–29	1049 (9.38)	0.49 (0.46, 0.52)	− 2.87 (− 4.36, − 1.45)	518 (4.63)	0.25 (0.23, 0.28)	− 2.36 (− 4.53, − 0.27)	
30–39	1117 (9.98)	0.54 (0.51, 0.58)	− 3.87 (− 7.02, − 1.55)	530 (4.74)	0.26 (0.24, 0.28)	− 2.52 (− 6.3, 0.31)	
40–49	1328 (11.87)	0.65 (0.62, 0.69)	− 5.24 (− 8.46, − 3.28)	531 (4.75)	0.25 (0.23, 0.28)	− 3.08 (− 5.36, − 1.06)	
50–59	1282 (11.46)	0.7 (0.67, 0.74)	− 3.33 (− 4.33, − 2.39)	625 (5.59)	0.32 (0.3, 0.35)	− 3.37 (− 4.86, − 1.95)	
60–69	1031 (9.22)	0.85 (0.8, 0.9)	− 4.67 (− 6.09, − 3.3)	704 (6.29)	0.52 (0.48, 0.56)	− 4.26 (− 5.91, − 2.59)	
70–79	800 (7.15)	1.16 (1.08, 1.24)	− 3.77 (− 5.15, − 2.48)	811 (7.25)	0.93 (0.87, 1)	− 3.23 (− 6.2, − 0.85)	
80+ 	402 (3.59)	1.12 (1.01, 1.23)	− 3.63 (− 7.29, − 0.42)	460 (4.11)	0.75 (0.68, 0.82)	-5.66 (− 8.27, − 3.55)	
Hispanic	
Age groups	Men	Women	
Case (%)	ASIR (95% CI)	AAPC (95% CI)	Case (%)	ASIR (95% CI)	AAPC (95% CI)	
20+ 	1398 (64.54)	0.79 (0.74, 0.84)	− 4.48 (− 5.88, − 3.1)	768 (35.46)	0.44 (0.41, 0.47)	− 2.41 (− 5.07, 0.31)	
20–29	204 (9.42)	0.33 (0.29, 0.38)	− 1.48 (− 7.35, 3.73)	96 (4.43)	0.17 (0.14, 0.21)	− 1.46 (− 7.02, 5)	
30–39	298 (13.76)	0.54 (0.48, 0.6)	− 3.66 (− 7.19, − 0.35)	111 (5.12)	0.21 (0.18, 0.26)	− 4.21 (− 7.94, − 0.73)	
40–49	305 (14.08)	0.7 (0.62, 0.78)	− 4.28 (− 6.35, − 2.3)	92 (4.25)	0.21 (0.17, 0.26)	N/A	
50–59	232 (10.71)	0.8 (0.7, 0.91)	− 5.3 (− 9.64, − 1.37)	133 (6.14)	0.44 (0.37, 0.52)	− 5.3 (− 8.48, − 2.19)	
60–69	178 (8.22)	1.17 (1, 1.36)	− 4.54 (− 7.36, − 1.44)	140 (6.46)	0.79 (0.66, 0.93)	N/A	
70–79	135 (6.23)	1.86 (1.56, 2.2)	− 3.14 (− 6.62, 0.69)	131 (6.05)	1.34 (1.12, 1.59)	2.08 (− 5.34, 12.22)	
80+ 	46 (2.12)	1.41 (1.03, 1.88)	N/A	65 (3.00)	1.2 (0.93, 1.53)	− 6.36 (− 16.49, 3.46)	
NHB	
Age groups	Men	Women	
Case (%)	ASIR (95% CI)	AAPC (95% CI)	Case (%)	ASIR (95% CI)	AAPC (95% CI)	
20+ 	833 (63.73)	0.76 (0.7, 0.81)	-4.3 (− 7.06, − 2.12)	474 (36.27)	0.38 (0.34, 0.41)	− 2.32 (− 5.4, 0.39)	
20–29	137 (10.48)	0.52 (0.43, 0.61)	− 7.13(− 10.74, − 3.54)	66 (5.05)	0.24 (0.19, 0.31)	N/A	
30–39	180 (13.77)	0.78 (0.67, 0.9)	− 2.23 (− 5.03, 0.41)	96 (7.35)	0.37 (0.3, 0.46)	− 2.4 (− 7.06, 2.47)	
40–49	217 (16.60)	0.95 (0.83, 1.09)	− 4.23 (− 8.07, − 0.97)	97 (7.42)	0.38 (0.3, 0.46)	− 1.08 (− 4.96, 2.88)	
50–59	173 (13.24)	0.91 (0.78, 1.06)	− 1.47 (− 5.17, 2.39)	92 (7.04)	0.42 (0.34, 0.51)	− 1.29 (− 4.87, 2.68)	
60–69	81 (6.20)	0.71 (0.56, 0.88)	− 4.79 (− 8.76, − 0.79)	59 (4.51)	0.41 (0.31, 0.52)	− 6.24 (− 12.73, 0.12)	
70–79	32 (2.45)	0.59 (0.4, 0.83)	N/A	49 (3.75)	0.59 (0.44, 0.78)	N/A	
80+ 	13 (0.99)	0.55 (0.29, 0.94)	N/A	15 (1.15)	0.31 (0.17, 0.52)	N/A	
NHW	
Age groups	Men	Women	
Case (%)	ASIR (95% CI)	AAPC (95% CI)	Case (%)	ASIR (95% CI)	AAPC (95% CI)	
20+ 	4452 (61.71)	0.71 (0.69, 0.73)	− 4.2 (− 4.82, − 3.71)	2762 (38.29)	0.39 (0.38, 0.41)	− 3.57 (− 4.28, − 2.96)	
20–29	645 (8.94)	0.61 (0.57, 0.66)	− 2.49 (− 4.13, − 0.97)	315 (4.37)	0.31 (0.28, 0.34)	− 2.21 (− 4.61, 0.01)	
30–39	589 (8.16)	0.55 (0.51, 0.6)	− 4.07 (− 6.95, − 2.1)	298 (4.13)	0.28 (0.25, 0.32)	− 0.66 (− 5.76, 2.44)	
40–49	752 (10.42)	0.63 (0.59, 0.68)	− 7.61(− 10.44, − 4.49)	322 (4.46)	0.27 (0.24, 0.3)	− 2.6 (− 5.48, − 0.15)	
50–59	815 (11.30)	0.68 (0.63, 0.73)	− 2.93 (− 3.93, − 2.01)	376 (5.21)	0.3 (0.27, 0.34)	− 3.58 (− 5.12, − 2.18)	
60–69	730 (10.12)	0.85 (0.79, 0.91)	− 4.89 (− 6.58, − 3.3)	487 (6.75)	0.53 (0.48, 0.58)	− 4.99 (− 7.06, − 3)	
70–79	599 (8.30)	1.16 (1.07, 1.26)	− 3.09 (− 5.42, − 1.19)	603 (8.36)	0.96 (0.88, 1.04)	− 3.46 (− 5.53, − 1.62)	
80+ 	322 (4.46)	1.15 (1.02, 1.28)	− 5.28 (− 9.32, − 1.87)	361 (5.00)	0.76 (0.68, 0.84)	− 4.52 (− 7.31, − 2.26)	
NHW, non-Hispanic White; NHB, non-Hispanic Black; ASIR, age-standardized incidence rate; CI, confidence interval; AAPC, average annual percent change; N/A, not available.

Men experienced a slight decrease in incidence rates between the age groups of 20–24 and 25–29, followed by a steady increase reaching a peak at 80–84. Women saw minimal fluctuations in the incidence rate between the ages of 20 and 44. From this point onward, the incidence rate progressively increased, reaching its peak at 75–79. Men consistently exhibited higher incidence rates compared to women (Fig. S8).

Nodular sclerosis Hodgkin lymphoma (NSHL)

Over 2000–2019, 35,534 cases of NSHL in all age groups in the US were reported. The majority of the cases were men (50.23%), NHWs (70.58%), and between 20 and 29 years old (67.47%). The ASIR per 100,000 population was 1.72 (1.70, 1.75) for men and 1.65 (1.63, 1.67) for women. Both sexes experienced a significant decline in ASIRs over 2000–2019 (AAPC: − 2.48% [− 3.12, − 1.80] for men and AAPC: − 2.24% [− 2.64, − 1.82] for women). NHW men had the highest ASIR (2.16 [2.13, 2.20]). Hispanic men exhibited the greatest decline in ASIRs between 2000 and 2019 (AAPC: − 2.89% [− 4.42, − 0.95]) (Table 5, Figs. S9–S11). The details of incidence trends for males and females are provided in Appendix 1.Table 5 Counts and age-standardized rate of nodular sclerosis Hodgkin lymphoma incidence per 100,000 and average annual percent change from 2000 to 2019 in the United States, by age, sex, and race.

All race/ethnicities	
Age group (years)	Men	Women	
Case (%)	ASIR (95% CI)	AAPC (95%CI)	Case (%)	ASIR (95% CI)	AAPC (95%CI)	
20+ 	17,850 (50.23)	1.72 (1.7, 1.75)	− 2.48 (− 3.12, − 1.8)	17,684 (49.77)	1.65 (1.63, 1.67)	-2.24 (− 2.64, − 1.82)	
20–29	5436 (15.30)	2.55 (2.48, 2.62)	− 2 (− 2.8, − 1.21)	6546 (18.42)	3.2 (3.12, 3.27)	− 1.9 (− 2.42, − 1.4)	
30–39	4193 (11.80)	2.02 (1.96, 2.09)	− 2.94 (− 3.53, − 2.41)	4463 (12.56)	2.16 (2.09, 2.22)	− 2.43 (− 2.89, − 2.01)	
40–49	2957 (8.32)	1.46 (1.4, 1.51)	− 3.07 (− 4.06, − 2.21)	2467 (6.94)	1.2 (1.15, 1.25)	− 2.27 (− 3.21, − 1.43)	
50–59	2109 (5.94)	1.16 (1.11, 1.21)	− 2.44 (− 3.14, − 1.78)	1498 (4.22)	0.79 (0.75, 0.83)	− 2.75 (− 3.6, − 1.95)	
60–69	1504 (4.23)	1.23 (1.17, 1.29)	− 2.21 (− 3.92, − 0.75)	1148 (3.23)	0.84 (0.79, 0.89)	− 3.35 (-4.68, − 2.01)	
70–79	1127 (3.17)	1.63 (1.54, 1.73)	− 1.36 (− 3.33, 0.81)	955 (2.69)	1.09 (1.02, 1.16)	− 3.2 (− 4.7, − 1.96)	
80+ 	524 (1.47)	1.45 (1.33, 1.58)	− 2.48 (− 4.15, − 0.77)	607 (1.71)	0.98 (0.91, 1.06)	− 3.15 (− 4.69, − 1.76)	
Hispanic	
Age groups	Men	Women	
Case (%)	ASIR (95% CI)	AAPC (95%CI)	Case (%)	ASIR (95% CI)	AAPC (95%CI)	
20+ 	2548 (48.68)	1.25 (1.19, 1.3)	− 2.89 (− 4.42, − 0.95)	2686 (51.32)	1.17 (1.12, 1.22)	− 2.64 (− 3.56, − 1.71)	
20–29	818 (15.63)	1.32 (1.23, 1.42)	0.03 (− 2.89, 3.63)	1150 (21.97)	2.06 (1.95, 2.19)	− 1.6 (− 2.7, − 0.48)	
30–39	591 (11.29)	1.06 (0.98, 1.15)	− 1.35 (− 3.18, 0.54)	662 (12.65)	1.26 (1.17, 1.36)	− 1.48 (− 4.02, 1.67)	
40–49	418 (7.99)	0.95 (0.86, 1.05)	− 2.53 (− 5.09, 0.15)	330 (6.30)	0.77 (0.69, 0.85)	− 1.73 (− 4.53, 1.28)	
50–59	287 (5.48)	0.99 (0.87, 1.11)	− 2.45 (− 4.04, − 0.7)	182 (3.48)	0.6 (0.52, 0.69)	− 4.09 (− 7.2, − 0.75)	
60–69	197 (3.76)	1.28 (1.1, 1.47)	− 5.82 (− 8.11, − 3.49)	168 (3.21)	0.94 (0.8, 1.09)	− 5.57 (− 9.48, − 1.57)	
70–79	169 (3.23)	2.32 (1.98, 2.7)	− 3.68 (− 5.67, − 1.57)	118 (2.25)	1.22 (1.01, 1.46)	− 4.62 (− 8.06, − 1.17)	
80+ 	68 (1.30)	2.06 (1.6, 2.61)	N/A	76 (1.45)	1.41 (1.11, 1.76)	0.14 (− 4.51, 6.73)	
NHB	
Age groups	Men	Women	
Case (%)	ASIR (95% CI)	AAPC (95%CI)	Case (%)	ASIR (95% CI)	AAPC (95%CI)	
20+ 	1682 (48.50)	1.46 (1.38, 1.53)	− 1.68 (− 3.78, 0.25)	1786 (51.50)	1.36 (1.29, 1.42)	− 1.89 (− 2.81, − 0.98)	
20–29	553 (15.95)	2.09 (1.92, 2.27)	− 1.82 (− 4.13, 0.54)	664 (19.15)	2.44 (2.26, 2.63)	− 2.88 (− 5.33, − 0.83)	
30–39	421 (12.14)	1.8 (1.63, 1.98)	− 3.11 (− 5.45, − 1)	499 (14.39)	1.92 (1.76, 2.1)	0.55 (− 3.37, 3.29)	
40–49	328 (9.46)	1.45 (1.29, 1.61)	− 1.08 (− 3.56, 1.28)	267 (7.70)	1.05 (0.93, 1.18)	− 1 (− 3.19, 1.13)	
50–59	209 (6.03)	1.11 (0.96, 1.27)	− 1.58 (− 3.78, 0.76)	176 (5.07)	0.8 (0.69, 0.93)	− 1.9 (− 4.56, 0.89)	
60–69	102 (2.94)	0.89 (0.72, 1.08)	− 6.36 (− 17.05, 1.59)	113 (3.26)	0.79 (0.65, 0.94)	− 2.89 (− 5.76, 0.2)	
70–79	52 (1.50)	0.96 (0.72, 1.26)	N/A	46 (1.33)	0.57 (0.41, 0.75)	N/A	
80+ 	17 (0.49)	0.73 (0.43, 1.18)	N/A	21 (0.61)	0.43 (0.27, 0.66)	N/A	
NHW	
Age groups	Men	Women	
Case (%)	ASIR (95% CI)	AAPC (95%CI)	Case (%)	ASIR (95% CI)	AAPC (95%CI)	
20+ 	12751 (50.84)	2.16 (2.13, 2.2)	− 2.38 (− 3.12, − 1.75)	12328 (49.16)	2.1 (2.06, 2.14)	− 1.99 (− 2.86, − 1.4)	
20–29	3724 (14.85)	3.54 (3.43, 3.66)	− 2.35 (− 2.98, − 1.76)	4303 (17.16)	4.22 (4.1, 4.35)	− 1.76 (− 3.1, − 0.79)	
30–39	2952 (11.77)	2.73 (2.64, 2.84)	− 2.8 (− 3.39, − 2.29)	3075 (12.26)	2.89 (2.79, 3)	− 2.39 (− 3.05, − 1.82)	
40–49	2095 (8.35)	1.77 (1.7, 1.85)	− 2.63 (− 3.7, − 1.82)	1777 (7.09)	1.51 (1.44, 1.59)	− 1.67 (− 2.71, − 0.78)	
50–59	1538 (6.13)	1.29 (1.23, 1.36)	− 2.32 (− 3.18, − 1.51)	1088 (4.34)	0.9 (0.85, 0.95)	− 2.25 (− 3.25, − 1.32)	
60–69	1144 (4.56)	1.33 (1.25, 1.41)	− 1.69 (− 4.68, 0.41)	831 (3.31)	0.89 (0.83, 0.96)	− 2.93 (− 4.32, − 1.52)	
70–79	876 (3.49)	1.71 (1.59, 1.82)	− 0.7 (− 2.85, 1.84)	760 (3.03)	1.2 (1.12, 1.29)	− 3.17 (− 4.76, − 1.71)	
80+ 	422 (1.68)	1.5 (1.36, 1.65)	− 1.92 (− 3.84, 0.01)	494 (1.97)	1.03 (0.94, 1.13)	− 3.59 (− 5.34, − 2.12)	
NHW, non-Hispanic White; NHB, non-Hispanic Black; ASIR, age-standardized incidence rate; CI, confidence interval; AAPC, average annual percent change; N/A, not available.

Both sexes showed declines in incident cases with advancing age. Moreover, both sexes revealed decreases in incidence rates, reaching the minimum rate at 55–59 age group. Subsequently, they increased until 75–79 age group for both sexes. Men exhibited higher incidence rates compared to women in all age groups except for the ages of 20–39 years (Fig. S12).

Classical Hodgkin lymphoma not otherwise specified (CHL-NOS)

From 2000 to 2019, there were 20,139 CHL-NOS cases in all age groups in the US. The majority of cases were men (57.91%), NHWs (63.46%), and aged 20–29 years (17.00%). The ASIR per 100,000 population was 1.16 (1.13, 1.18) for men and 0.76 (0.74, 0.78) for women. Both sexes experienced increases in ASIRs between 2000 and 2019 (AAPC: 2.60% [2.07, 3.22] for males and AAPC: 3.89% [3.29, 4.70] for females) (Table 6, Figs. S13–S15). The details of incidence trends for males and females are provided in Appendix 1.Table 6 Counts and age-standardized rate of classical Hodgkin lymphoma not otherwise specified incidence per 100,000 and average annual percent change from 2000 to 2019 in the United States, by age, sex, and race.

All race/ethnicities	
Age group (years)	Men	Women	
Case (%)	ASIR (95% CI)	AAPC (95%CI)	Case (%)	ASIR (95% CI)	AAPC (95%CI)	
20+ 	11,663 (57.91)	1.16 (1.13, 1.18)	2.6 (2.07, 3.22)	8476 (42.09)	0.76 (0.74, 0.78)	3.89 (3.29, 4.7)	
20–29	1841 (9.14)	0.86 (0.82, 0.9)	4.44 (3.61, 5.47)	1582 (7.86)	0.77 (0.73, 0.81)	4.46 (3.41, 5.76)	
30–39	1828 (9.08)	0.89 (0.85, 0.93)	2.74 (1.61, 4.01)	1329 (6.60)	0.64 (0.61, 0.68)	4.98 (4.26, 5.87)	
40–49	1854 (9.21)	0.91 (0.87, 0.95)	2.13 (1.3, 3.06)	1106 (5.49)	0.53 (0.5, 0.56)	3.45 (2.31, 4.76)	
50–59	2009 (9.98)	1.1 (1.05, 1.15)	2.69 (1.92, 3.6)	1099 (5.46)	0.57 (0.54, 0.61)	2.67 (1.41, 4.18)	
60–69	1768 (8.78)	1.45 (1.39, 1.52)	1.88 (0.7, 3.36)	1230 (6.11)	0.9 (0.85, 0.96)	1.93 (0.64, 3.5)	
70–79	1502 (7.46)	2.18 (2.07, 2.29)	1.95 (0.99, 3.04)	1222 (6.07)	1.4 (1.32, 1.48)	1.67 (− 0.21, 3.86)	
80+ 	861 (4.28)	2.4 (2.24, 2.56)	6.42 (0.83, 13.02)	908 (4.51)	1.46 (1.37, 1.56)	1.72 (0.3, 3.33)	
Hispanic	
Age groups	Men	Women	
Case (%)	ASIR (95% CI)	AAPC (95%CI)	Case (%)	ASIR (95% CI)	AAPC (95%CI)	
20+ 	2309 (60.02)	1.37 (1.31, 1.44)	3.01 (1.92, 4.43)	1538 (39.98)	0.82 (0.78, 0.87)	3.19 (2.2, 4.52)	
20–29	405 (10.53)	0.65 (0.59, 0.72)	5.06 (2.99, 7.72)	347 (9.02)	0.62 (0.56, 0.69)	6.83 (4.91, 9.67)	
30–39	408 (10.61)	0.74 (0.67, 0.81)	2.03 (0.17, 4.25)	236 (6.13)	0.45 (0.39, 0.51)	5.44 (3.47, 8.17)	
40–49	387 (10.06)	0.88 (0.8, 0.98)	0.47 (− 1.72, 3.07)	198 (5.15)	0.46 (0.4, 0.53)	3.82 (1.92, 6.41)	
50–59	386 (10.03)	1.33 (1.2, 1.47)	1.96 (− 0.6, 5.49)	209 (5.43)	0.69 (0.6, 0.79)	1.08 (− 1.07, 3.89)	
60–69	327 (8.50)	2.14 (1.91, 2.39)	2.69 (0.99, 4.97)	217 (5.64)	1.22 (1.07, 1.4)	2.55 (0.12, 6.01)	
70–79	280 (7.28)	3.8 (3.37, 4.28)	3.38 (0.85, 6.98)	220 (5.72)	2.24 (1.96, 2.56)	0.9 (− 3.33, 11.57)	
80+ 	116 (3.02)	3.54 (2.92, 4.25)	N/A	111 (2.89)	2.05 (1.69, 2.47)	0.32 (− 3.64, 6.18)	
NHB	
Age groups	Men	Women	
Case (%)	ASIR (95% CI)	AAPC (95%CI)	Case (%)	ASIR (95% CI)	AAPC (95%CI)	
20+ 	1488 (58.86)	1.37 (1.3, 1.45)	2.42 (1.36, 3.68)	1040 (41.14)	0.81 (0.76, 0.86)	3.4 (2.12, 4.94)	
20–29	270 (10.68)	1.02 (0.91, 1.15)	3.58 (0.29, 8.21)	210 (8.31)	0.77 (0.67, 0.88)	3.87 (1.43, 7.06)	
30–39	320 (12.66)	1.39 (1.24, 1.56)	2.62 (0.28, 5.4)	207 (8.19)	0.8 (0.7, 0.92)	4.69 (1.31, 9.09)	
40–49	337 (13.33)	1.48 (1.33, 1.65)	1.36 (− 0.52, 3.38)	195 (7.71)	0.76 (0.66, 0.87)	2.03 (− 1, 5.31)	
50–59	297 (11.75)	1.57 (1.4, 1.76)	1.79 (− 0.35, 4.38)	173 (6.84)	0.78 (0.67, 0.91)	2.77 (− 0.48, 7.09)	
60–69	152 (6.01)	1.36 (1.15, 1.59)	1.93 (− 1.48, 6.7)	130 (5.14)	0.89 (0.74, 1.06)	2.45 (− 1.11, 7.73)	
70–79	79 (3.13)	1.45 (1.14, 1.81)	3.06 (0.45, 6.85)	75 (2.97)	0.9 (0.71, 1.13)	5.76 (3.16, 9.91)	
80+ 	33 (1.31)	1.43 (0.98, 2.01)	N/A	50 (1.98)	1.04 (0.77, 1.38)	0.22 (− 4.61, 6.06)	
NHW	
Age groups	Men	Women	
Case (%)	ASIR (95% CI)	AAPC (95%CI)	Case (%)	ASIR (95% CI)	AAPC (95%CI)	
20+ 	7295 (57.08)	1.16 (1.13, 1.19)	2.65 (2.09, 3.27)	5486 (42.92)	0.81 (0.78, 0.83)	3.81 (2.86, 5.09)	
20–29	1020 (7.98)	0.97 (0.91, 1.03)	4.37 (2.81, 6.3)	914 (7.15)	0.9 (0.84, 0.96)	3.81 (2.61, 5.21)	
30–39	1005 (7.86)	0.93 (0.88, 0.99)	3.1 (1.17, 5.3)	791 (6.19)	0.75 (0.7, 0.8)	4.94 (3.63, 6.52)	
40–49	1064 (8.32)	0.89 (0.84, 0.94)	2.86 (1.84, 3.9)	660 (5.16)	0.55 (0.51, 0.59)	3.62 (1.73, 5.66)	
50–59	1228 (9.61)	1.03 (0.97, 1.08)	2.8 (2.08, 3.6)	685 (5.36)	0.56 (0.52, 0.6)	2.47 (0.64, 4.54)	
60–69	1211 (9.48)	1.41 (1.33, 1.49)	1.4 (0.16, 2.92)	840 (6.57)	0.91 (0.85, 0.97)	1.33 (− 0.4, 3.38)	
70–79	1086 (8.50)	2.12 (1.99, 2.25)	1.87 (− 0.2, 4.29)	876 (6.85)	1.39 (1.3, 1.48)	1.29 (− 0.6, 3.39)	
80+ 	681 (5.33)	2.43 (2.25, 2.62)	5.56 (0.46, 11.31)	720 (5.63)	1.49 (1.39, 1.61)	1.89 (− 0.03, 3.99)	
NHW, non-Hispanic White; NHB, non-Hispanic Black; ASIR, age-standardized incidence rate; CI, confidence interval, AAPC, average annual percent change; N/A, not available.

The incident cases of CHL-NOS in men remained relatively stable from ages 20 to 69, after which it began to decline, reaching its lowest point over 85. In contrast, there was a fluctuation for women, decreasing from 20–24 to 50–54, followed by an increase to 60–64 and stabilization until 70–74, then a subsequent decline. Men had minimal fluctuation from 20–24 to 45–49 in terms of incidence rates. Then, the incidence rate of men experienced an increase until 80–84 years, followed by a steep decline. For women, there was a minimal decline from 20–24, reaching the minimum at 50–54, and from this point onward, there was a steady increase until 80–84. In all age groups, men exhibited higher incidence rates than women (Fig. S16).

Nodular lymphocyte prominent Hodgkin lymphoma (NLPHL)

Over 2000–2019, there were 4,063 cases of NLPHL in the US across all age groups. The majority of cases were observed in men (64.66%), NHWs (58.85%), and cases between 40 and 49 years (19.71%). The ASIR per 100,000 population was 0.25 (0.24, 0.26) for men and 0.13 (0.12, 0.14) for women. Both sexes experienced significant increases in ASIRs over 2000–2019 (AAPC: 4.95% [3.77, 6.45] for men and AAPC: 6.33% [5.10, 7.94] for women) (Table 7, Figs. S17–S19). The details of incidence trends for males and females are provided in Appendix 1.Table 7 Counts and age-standardized rate of nodular lymphocyte prominent Hodgkin lymphoma incidence per 100,000 and average annual percent change from 2000 to 2019 in the United States, by age, sex, and race.

All race/ethnicities	
Age group (years)	Men	Women	
Case (%)	Delayed ASIR (95% CI)	AAPC (95%CI)	Case (%)	Delayed ASIR (95% CI)	AAPC (95%CI)	
20+ 	2627 (64.66)	0.25 (0.24, 0.26)	4.95 (3.77, 6.45)	1436 (35.34)	0.13 (0.12, 0.14)	6.33 (5.1, 7.94)	
20–29	466 (11.47)	0.22 (0.2, 0.24)	3.45 (1.57, 5.73)	189 (4.65)	0.09 (0.08, 0.11)	N/A	
30–39	525 (12.92)	0.26 (0.23, 0.28)	4.39 (1.93, 7.43)	189 (4.65)	0.09 (0.08, 0.11)	2.59 (− 1.28, 7.51)	
40–49	534 (13.14)	0.26 (0.24, 0.28)	6.75 (5, 9)	267 (6.57)	0.13 (0.11, 0.14)	8.98 (7.38, 11.27)	
50–59	520 (12.80)	0.28 (0.26, 0.31)	4.94 (3.14, 8.46)	305 (7.51)	0.16 (0.14, 0.18)	6.6 (4.72, 9.37)	
60–69	366 (9.01)	0.3 (0.27, 0.33)	3.52 (1.75, 6.03)	275 (6.77)	0.2 (0.18, 0.23)	5.21 (1.61, 11.44)	
70–79	169 (4.16)	0.24 (0.21, 0.28)	3.4 (0.8, 7.12)	169 (4.16)	0.19 (0.16, 0.22)	5.83 (3.77, 8.74)	
80+ 	47 (1.16)	0.13 (0.09, 0.17)	N/A	42 (1.03)	0.07 (0.05, 0.09)	N/A	
Hispanic	
Age groups	Men	Women	
Case (%)	Delayed ASIR (95% CI)	AAPC (95%CI)	Case (%)	Delayed ASIR (95% CI)	AAPC (95%CI)	
20+ 	321 (64.46)	0.15 (0.14, 0.17)	3.57 (1.48, 6.56)	177 (35.54)	0.09 (0.08, 0.11)	4.2 (0.71, 9.74)	
20–29	84 (16.87)	0.14 (0.11, 0.17)	N/A	23 (4.62)	0.04 (0.03, 0.06)	N/A	
30–39	74 (14.86)	0.14 (0.11, 0.17)	3.4 (− 1.75, 10.64)	25 (5.02)	0.05 (0.03, 0.07)	N/A	
40–49	61 (12.25)	0.14 (0.11, 0.18)	N/A	44 (8.84)	0.1 (0.07, 0.14)	N/A	
50–59	58 (11.65)	0.2 (0.15, 0.26)	N/A	34 (6.83)	0.11 (0.08, 0.16)	N/A	
60–69	26 (5.22)	0.17 (0.11, 0.25)	N/A	30 (6.02)	0.17 (0.11, 0.24)	N/A	
70–79	13 (2.61)	0.18 (0.09, 0.31)	N/A	16 (3.21)	0.16 (0.09, 0.27)	N/A	
80+ 	5 (1.00)	0.15 (0.05, 0.35)	N/A	5 (1.00)	0.09 (0.03, 0.21)	N/A	
NHB	
Age groups	Men	Women	
Case (%)	Delayed ASIR (95% CI)	AAPC (95%CI)	Case (%)	Delayed ASIR (95% CI)	AAPC (95%CI)	
20+ 	498 (50.51)	0.44 (0.41, 0.49)	5.98 (3.93, 8.93)	488 (49.49)	0.38 (0.35, 0.42)	6.14 (3.96, 9.31)	
20–29	82 (8.32)	0.31 (0.25, 0.38)	6.71 (3.33, 12.06)	64 (6.49)	0.24 (0.18, 0.3)	N/A	
30–39	106 (10.75)	0.45 (0.37, 0.55)	5.41 (0.85, 11.66)	97 (9.84)	0.37 (0.3, 0.46)	N/A	
40–49	130 (13.18)	0.57 (0.47, 0.67)	N/A	119 (12.07)	0.46 (0.38, 0.55)	9.35 (6.99, 13.01)	
50–59	103 (10.45)	0.55 (0.45, 0.66)	N/A	103 (10.45)	0.47 (0.38, 0.57)	N/A	
60–69	56 (5.68)	0.5 (0.37, 0.65)	N/A	71 (7.20)	0.49 (0.39, 0.62)	N/A	
70–79	18 (1.83)	0.33 (0.19, 0.52)	N/A	30 (3.04)	0.36 (0.25, 0.52)	N/A	
80+ 	3 (0.30)	0.12 (0.03, 0.37)	N/A	4 (0.41)	0.09 (0.02, 0.22)	N/A	
NHW	
Age groups	Men	Women	
Case (%)	Delayed ASIR (95% CI)	AAPC (95%CI)	Case (%)	Delayed ASIR (95% CI)	AAPC (95%CI)	
20+ 	1684 (70.43)	0.27 (0.26, 0.28)	4.87 (4.02, 5.84)	707 (29.57)	0.1 (0.09, 0.11)	6.25 (4.73, 8.28)	
20–29	273 (11.42)	0.26 (0.23, 0.29)	2.01 (− 0.26, 4.63)	92 (3.85)	0.09 (0.07, 0.11)	N/A	
30–39	324 (13.55)	0.3 (0.27, 0.34)	4.93 (1.65, 8.98)	60 (2.51)	0.06 (0.04, 0.07)	N/A	
40–49	318 (13.30)	0.26 (0.24, 0.29)	6.57 (4.85, 8.63)	95 (3.97)	0.08 (0.06, 0.1)	N/A	
50–59	333 (13.93)	0.28 (0.25, 0.31)	4.85 (3.06, 7.96)	148 (6.19)	0.12 (0.1, 0.14)	6.74 (3.38, 11.79)	
60–69	269 (11.25)	0.31 (0.27, 0.35)	3.32 (1.18, 6.27)	160 (6.69)	0.17 (0.15, 0.2)	N/A	
70–79	131 (5.48)	0.25 (0.21, 0.3)	3.53 (0.58, 7.66)	120 (5.02)	0.19 (0.16, 0.23)	5.45 (2.44, 9.9)	
80+ 	36 (1.51)	0.13 (0.09, 0.18)	N/A	32 (1.34)	0.07 (0.05, 0.1)	N/A	
NHW, non-Hispanic White; NHB, non-Hispanic Black; ASIR, age-standardized incidence rate; CI, confidence interval; AAPC, average annual percent change; N/A, not available.

There was an overall increase in incidence rates in both sexes, peaking at 55–59 for men and 65–69 for women. Subsequently, both sexes experienced a decline until ages over 85 years. Also, men exhibited higher incidence rates compared to women (Fig. S20).

Discussion

Our study primarily delineated the incidence trend of HL as a relatively rare hematological malignancy in the US. As a SEER program-based study that exclusively assessed the US population, we mainly focused on different epidemiological features of the various HL histopathological subtypes in 20 years and especially presented updates on trend changes from the early 2000s, which was also partly discussed by Glaser et al.33 and Evens et al.34, up to 2019, when the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started to spread globally and drastically influenced cancer diagnostic and management processes. COVID-19 pandemic caused a significant decline in the ASIRs of the HL cases among all races and age groups. Our data demonstrated that the overall incidence of HL in both sexes decreased between 2000 and 2019 and had an approximately doubled pace in the last five years. However, the CHL-NOS subtype and NLPHL showed an increasing trend. Generally, in all HL subtypes, men comprised the higher proportion of the population and had an overall higher delayed ASIR, with the highest incidence rate among the ages 70 years and older. However, in the age group of 20–29, women represented slightly more cases and had higher ASIRs. While assessing the age composition, the 20–29 individuals were considered the most incident age group in the HL subtype population, except for the NLPHL and LR/MC/LD, in which the cases in their 40s and 50s, respectively, are the dominant age cluster. The present study demonstrated that NHW cases were the most frequent racial subgroup in the HL population in the US, although varieties were seen among distinct histological entities. From the histopathological point of view, among the NSHL subtype, NHWs had the highest age-adjusted incidence rates. In contrast, Hispanics showed dominancy in the MC subtype, which was also pointed out in the study performed by Evens et al.34. Moreover, NHB was the leading racial subgroup in NLPHL and CHL-NOS, as depicted in the survey conducted by Shenoy et al.35. Despite the overall decline in the HL incidence in all racial subgroups, NHB women depicted a positive AAPC.

Our analysis revealed that our data almost aligns with the previous studies conducted in the US. An early SEER-based paper that evaluated the population data from 1992 to 201133 showed that the CHL incidence trend, as the most common HL subgroup comprising 95% of its cases, was nearly stable until 2007 and subsequently started to diminish. In our study, the incidence of CHL could be subclassified based on age categories. The age group 30–69 had a diminishing incidence without any joinpoint (JP) while illustrating the joinpoint regression analysis. The age range of 20–29 and 70–79 revealed a steady decline from its JP around 2004–2006. Despite the mentioned study in which the CHL incidence of the age group 80+ was relatively increased from 2008 to 201133, our analysis indicated that their incidence patterns declined from 2004 to 2019. In a detailed evaluation of our data regarding NSHL, the most common subtype of classic HL which includes almost half of all CHL instances, we obtained that men showed a declining incidence pattern without a JP. Still, women showed an incidence rise from 2011 to 2019, probably explained in the following text, subsequent to a decreasing trend discussed by Glaser et al.33. While analyzing the NSHL statistics of the racial subgroups, both studies suggest a more rapid decrease that follows a slower decline with a JP around 2009–2011 in Hispanics and 2015 in NHWs. In our study, when analyzing the LR/MC/LD population concerning age subgroups, an overall decrease without JP was observed, while an initial rise in age groups 20–29, 40–49, and 70–79 was seen. Glaser et al. substantially agreed with our results, and Huang et al.1, relying on a worldwide evaluation, pointed out that the MC incidence decline was accelerated from 2009–2010.

In our study, NHWs’ highest ASIR was around 55–65 in males and 20–29 in females, while it was 20–29 in both sexes in Evens et al.34, which evaluated the HL trend in the US population data in 1992–2007. However, our study presented the age group of 30–39 in men and the age group of 20–29 in women as the NHB’s highest ASIRs, whereas it was 40–49 in males and 30–39 in females of the Blacks in the previous study. This reveals an approximately 10-year shift in the highest incidence age of the mentioned racial subgroup. Both sexes of Hispanics showed the highest ASIR of the 70–79 age group in both studies. Although this increasing trend in NHBs could be related to population aging, there is no convincing reason for this growing ASIRs in NHW males. Additionally, Evens et al.34 demonstrated that whites had the highest incidence in patients aged under 65 years, and Hispanics had the highest incidence in patients aged more than 65 years, which is also confirmed by our findings. It has been discussed in either of previous studies conducted on the US population that the declining trend of the CHL, accompanied by relevant and predictable changes in its major NSHL subtype and the presence of normal variations in diverse age and sex trends, is proof of a realistic change. Still, the MC rate decrement and similar reciprocal two–three-fold increments in NOS incidence with an age- and sex-disproportional pattern bring underlying false incidence changes in the mind. The identical incidence trend pattern of MC between 1992 and 1996 and the pattern of NOS between 2007 and 2011, revealed by Glaser et al., potentiates the proposed theory. Regarding the recent definition of NLP as a new disease entity, an increased incidence rate of NLP during the timespan among different subgroups could be reasonable and is also mentioned in both discussed articles. However, an actual incidence change cannot be overseen.

In accordance with our study, global patterns in HL incidence reported by Shen et al.36 revealed an ASIR decrement from 1999 to 2019. Global 2020 investigation has revealed that Australia, New Zealand, and the US are among the countries with the highest ASIR, after South, North, and West European countries. In male populations, a higher risk of HL is related with higher Gross Domestic Product (GDP) per capita, smoking (odds ratio = 1.1), obesity (a 10% higher risk for a body mass index increase of 5 kg/m2), and hypertension. In the women population, smoking and obesity are related to a higher risk of HL. Although alcohol consumption may increase the risk of HL in women aged under 50, smoking is more considerable in women aged above 50 years1. According to a study on national cancer registry data in Iran, the crude incidence rates of cancer were 10.41 and 7.28 among males and females, respectively, in 2016, reflecting increases of 3.4% and 4.3% in males and females, respectively, from 2000 to 201637. Consequently, the incidence rates in Iran was higher than those in the US. However, it should be noted that there are differences in the reported measures (crude rate vs. age-standardized rate). Additionally, the study based on cancer registry in Iran did not differentiate between various types of hematological cancers, combining all cases of HL, non-HL, leukemia, and multiple myeloma together37. Moreover, another study in Tehran, the capital of Iran, showed that the ASIRs of hematological cancers among men and women were 99.5 and 16.2 per 100,000 over 1999–2014, respectively38. The rising incidence and greater ASIRs might be due to population growth or ageing, smoking, and air pollution39,40. Our study declares that NSHL had a decreasing rate from about 2005 to 2006, which could be related to approximately 1.8% overall GDP decline in the US from 2006 to 2016. Although GDP is not the only reason, it can be one of the contributing factors along with the reduction of smoking prevalence41. The lower incidence of HL in countries with lower GDP/income is related to a lack of powerful equipment and resultant undiagnosed or misclassified cases36. In a general review of this study1, the increasing trend of HL incidence in younger people and women is associated with the increase in obesity and metabolic diseases. The global weight gain and obesity in women has increased from 30% in 1980 to 38% in 2013 and 41.9% in 2018, which also had a higher pace than men in the recent three decades42. The global burden of the disease study conducted from the data collected between 1980 and 2015 confirmed that a higher sociodemographic index correlates with an increased prevalence of obesity43. Additionally, the study delineated that women had higher prevalence of obesity in all age groups and the most prominent increase in the obesity rate belongs to early adulthood43. Otherwise, between 1985 and 2014, central obesity had a more significant escalation in younger ages (15–40 age) and Asian women represented a higher HL incidence in global investigations44. A study comparing HL between native and US-born Asians showed that US born-Asian had more than twice the prevalence of HL, which also makes the role of environmental factors more evident45. Otherwise, a study revealed that a better quality of life in early childhood, possibly evident in US-born children, positively correlates with metabolic disorders and consequently would increase the possibility of HL at younger ages46. Among the 21 regions of our planet assessed for further clarifying the epidemiology of the lymphoma by Shen et al.36, Caribbean populations had the highest ASIRs for HL which was postulated to be associated with prominent EBV and HIV infection prevalence there.

In respect of other environmental factors affecting the histopathological trend of NSHL, the recent decrease in NSHL in our study could mainly be attributed to a lowered rate of early social isolation47,48. Studies have reported associations between lowered risk of lymphoma and larger sibship size and/or later birth order for lymphoid49. Besides, pre-school attendance is a known protective condition for this subtype reduced rate50. None of these factors could explain the difference in sex incidence in NSHL patients. While assessing the causes of higher HL in females, as it was seen in our study, in which the overall CHL rate was higher in females in the 20–35 age range. Zhu et al. presented that multi-parity and younger age first gravidity reduced the HL risk. Subsequently, reluctance to have more children and pregnancy at an older age impose a higher risk of NSHL in younger nulliparous women. Also, Zhu et al.51 concluded that Aspirin consumption, smoking, and EBV infection could not reasonably discuss the sex incidence difference in NSHL patients. Evens et al.34 declared that in their 15-year study, the rise in HL incidence mainly occurred in the 15–45-year ages, and cases predominantly belonged to the NS subtype. It has been demonstrated that NS subgroup positively correlated to socioeconomic status improvement and higher quality of care of the population of the study, which directly correlates with increased risk of metabolic syndrome34,52.

Regarding NSHL, the incidence rate in the US did not show a distinguishable change similar to other studies assessing NSHL trends in distinct regions in the globe53–55, but noticeable increases were reported in Australia until 2006 and in Japan until 2008. For young adults, the rising incidence of NSHL has been reported previously. In Australia, the NSHL rate rose 5% from 1997 until 2006, and an overall decrease was mentioned. The Automated Childhood Cancer Information System association also reported an incidence rise of HL (mostly NSHL), approximately 1% and 3.5% in childhood and early adolescent between 15 and 19 years, respectively56. Our study concluded that the overall incidence of HL in the > 20-year population declined, which could be discussed by the study of Hjalgrim et al.57, reporting that HL incidence markedly diminished in patients over 40 years, but children and young adults showed a discernable rise in the HL rate between 1978 and 1997.

In the study by Glaser et al. in 201533, MC and NOS had diminished and raised incidence rates, respectively, which aligned with previous studies in the US and Australia58,59. The MC rate lessened in distinct racial subgroups between 1988–1992 and 2000–2004, mainly due to diagnostic problems and misclassification of subtypes. This principally resulted from the substitution of fine needle aspiration biopsy and core needle biopsy with conventional excisional biopsy, from which a small amount of body tissue with poorer quality was obtained60,61. About 12% of the obtained samples, primarily diagnosed as NOS, were identified to have insufficient cells. Modified tissue gathering procedures affect the NSHL detection less prominently than MC due to the preserved subtype morphology, even with a needle biopsy. Reduced specificity in histological classification caused complicated and less successful trend analysis of distinct HL subtypes and assessment of environmental cofounders. Furthermore, lower specified classification of HL subtypes caused NOS to be the second most common CHL subclass following NSHL, diminishing the need for genetic profiling, transcriptional analysis, and overall healthcare diagnosis costs62–64. Although differentiating various HL subgroups did not exert a major effect on treatment adjustment, it would assist in predicting patient survival and choosing tailored treatment64–66. As stated by Ye et al.54 in the Canadian society, a reasonable mechanism for HL decline in our study, is reduced HIV prevalence. HIV prevalence decreased by 38% from 2010 to 2022 globally, which could be a potent factor in the HL decreasing trend, especially in the MC subtype. As Grulich et al.67 declared, HIV infection could raise the risk of HL by 11 times. In contrast to the APC of MC subtype in the US, which demonstrated a platue since mid-1990s and a fall following the early 2000s, with the highly active antiretroviral therapy treatment being launched and widely used68 and more adoption to a westernized life style69, the MC subtype ASIR in the Japanese population raised from 1993 to 2008 delineated by Chihara et al.70. This could be at least partially explained by the increasing HIV rate in the same era, despite the nearly constant or slightly increasing HIV rate in Japan from 200671. Glaser et al.33 and McNally et al.72 reported that MC is associated with low socioeconomic status. Consequently, life welfare improvement lowered the rate of MC. An approximately 50% lowered smoking rate since 200541, which was confirmed to be more significant in countries with higher income73, and a westernized lifestyle are also considered as reasons for the decreased MC rate in the US. Although Juntikka et al.53 affirmed that NS was more common in women at a younger age, it emphasized that MC was more common in men in all age subgroups and was mostly prevalent in older ages. This report in Finland discussed that a significant MC decrease in ASIR was seen in their 20-year survey. Younger ages had a more appreciable ASIR decline, but there was no considerable decrement in older adults. The effect of EBV on the MC trend and the relation between the anti-EBV antibodies and its associated cancers was investigated as a reason for this decline MC trend in the US74,75. Although no significant changes have been reported regarding LR, a considerable decrease in LD has been seen in Finland till 2015. NOS incidence has been constant during the study which strengthens the theory of HIV and EBV effect. Solans et al.55 additionally pointed out that HL incidence was higher in Southern Europe and lower in Eastern Europe and accused the EBV infection, HIV, socioeconomic factors, differences in diagnosis precision, and health system availability as the possible reasons.

In our study, similar to the study by Strobbe et al.76 in the Netherlands, an increased incidence of NLPHL had been reported. This study has confirmed previous studies that have pointed out the effect of pathology misclassification as 2.8% to 20%. NLPHL increase could be associated with several associated factors: (1) better and more widely recognition of this subtype as a new distinct disease entity in 1994, (2) further development of NLPHL diagnostic tools, immunohistochemistry technology and its availability leading to more accurate diagnosis of these cases, and (3) improvements in the recording process of hematologic malignancies in the hematopathologic laboratories since 2000. An article from Finland53 reported that NLPHL incidence has not made any remarkable changes. As suggested by our study, NLP was more common in men and was diagnosed at few younger ages in men. Although the main reason was unclear, one of the considerable reasons could be the wider distribution of a germline mutation in 11q22-23 site which initially detected in Finland.

Following the initial spread of SARS-CoV-2 and residing interpersonal restrictions, including social isolation, plenty of adverse effects harmed the healthcare system. Most healthcare costs were spent on diagnosis, medical treatment and rehabilitation of COVID-19 patients, and even most hospitals were specialized only for dealing with the pandemic77. Besides, patients were neglected due to the decline in the number of working medical staff either who affected with the disease or who were redirected from different centers to new viral disease centers exacerbates the condition. Not referring to general clinics or hospitals due to fear of getting COVID-19 and converting out-patient visits to telemedicine had significantly affected the patients with cancer or high probability to acquire one. Otherwise, low availability of imaging, difficulty of public transportation, and depressed emotional support had all negative effects on these patients78. These adverse effects were more evident at the pandemic's beginning because of the authority-organized lockdown and the health system's incapability of handling enormous patient load. In the first months after the initial disease spread, cancer screening was not performed thoroughly, and people did not pursue medical aid due to social anxiety and the stress of getting the disease. The decline in new cancer diagnoses was reported by 40–50% in most cancers compared to the previous year79. Also, most of the accomplished diagnoses were at an advanced stage, which is also confirmed about lung cancer in many studies80. Different studies have proved that delays in screening cause a considerable decrease in diagnosed cases and higher incidence in advanced stages of cancer reducing their survival rate81,82. All histological subgroups of HL in our study presented a lower incidence while comparing 2019 statistics with past years. This delay resulted in not starting treatment on time, increased mortality, and decreased survival. Also, in patients whose treatment has begun, the pandemic caused a delay in the regular continuation of the radiotherapy process. This irregular schedule, along with emotional injuries, was a disturbing factor for these patients. Investigations showed that approximately one out of three of lymphoma cases in the COVID-19 time were suffered from anxiety, depression, and post-traumatic stress disorder83. Also, studies have revealed that patients with cancers had a 60% higher risk of getting infected with COVID-1984. Chemotherapy drugs increased the risk of getting infected with COVID-19. COVID-19 caused more severe symptoms in these cases and higher mortality in patients with hematological malignancies77,85.

Our study had strengths and limitations which are necessary to be acknowledged. We used the large database of SEER for evaluating and clarifying the incidence patterns of histological subtypes of HL among adults in the US. Additionally, in this study we conducted JP regression analyses, parallelism and coincidence tests. Assessing pre- and post-COVID-19 effect on the incidence trend of HL was necessary and is counted on as a strength point of our study. On the other side, several limitations could be mentioned. Registered data are always considered to have several potential bias. Deficient central pathology reanalysis and lack of final diagnosis confirmation by a hematopathologist, and also refusing to resample and recode the previously diagnosed NOS subtypes all could contribute to increased risk of detection and classification bias. In this article, we merely focused on the incidence trend analysis and other studies are needed to further evaluate survival and region-based analysis of the data and evaluate the risk factor association of each subtype. Another distinguishable racial disparity of our study is that Asian/Pacific Americans were not considered as a distinct ethnicity which could potentially affect the way secular trends would be interpreted. However, they were included for reporting the overall numbers and rates. Reporting the results of our histopathological subgroup, it is worth mentioning that separate MC, LR, and LD subgroups are discussed in our article as one CHL subcategory which may interfere with analyses the each HL subtype separately.

Conclusions

Overall HL incidence and NSHL subtype, as the largest histopathological subtype of HL, decreased in 20 years in the US among both sexes, however, the CHL-NOS and NLPHL subtypes showed an increasing trend. The age group of 20–29 years comprises the majority of cases, and from the racial aspect, NHWs were the dominant subcategory. The COVID-19 pandemic resulted in an overall decline in the incidence of HL in all age groups, races, and sexes.

Supplementary Information

Supplementary Information 1.

Supplementary Information 2.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-69975-3.

Acknowledgements

We would like to thank the National Institute of Cancer staff and its collaborators of the Surveillance, Epidemiology, and End Results Program (SEER) who prepared the data.

Author contributions

SEM and SAN designed the study. SEM analyzed the data and performed the statistical analyses. SEM, SC, SM, AA, and SAN drafted the initial manuscript. SEM, ZY, and SAN critically edited and revised the initial draft of the manuscript. All authors reviewed the drafted manuscript for critical content. All authors approved the final version of the manuscript.

Data availability

The data presented in this study are available at https://seer.cancer.gov/data-software/.

Competing interests

The authors declare no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Huang J Pang WS Lok V Zhang L Lucero-Prisno DE 3rd Xu W Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: A global data analysis J. Hematol. Oncol. 2022 15 1 57 10.1186/s13045-022-01281-9 35546241
Huang, J. et al. Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: A global data analysis. J. Hematol. Oncol. 15(1), 57 (2022).35546241 10.1186/s13045-022-01281-9
2. Lees C Keane C Gandhi MK Gunawardana J Biology and therapy of primary mediastinal B-cell lymphoma: Current status and future directions Br. J. Haematol. 2019 185 1 25 41 10.1111/bjh.15778 30740662
Lees, C., Keane, C., Gandhi, M. K. & Gunawardana, J. Biology and therapy of primary mediastinal B-cell lymphoma: Current status and future directions. Br. J. Haematol. 185(1), 25–41 (2019).30740662 10.1111/bjh.15778
3. Sohani AR Hodgkin lymphoma and its differential diagnosis: New twists on an old challenge Surg. Pathol. Clin. 2023 16 2 287 346 10.1016/j.path.2023.02.002 37149361
Sohani, A. R. Hodgkin lymphoma and its differential diagnosis: New twists on an old challenge. Surg. Pathol. Clin. 16(2), 287–346 (2023).37149361 10.1016/j.path.2023.02.002
4. Amraee A Evazi MR Shakeri M Roozbeh N Ghazanfarpour M Ghorbani M Efficacy of nivolumab as checkpoint inhibitor drug on survival rate of patients with relapsed/refractory classical Hodgkin lymphoma: A meta-analysis of prospective clinical study Clin. Transl. Oncol. 2019 21 8 1093 1103 10.1007/s12094-018-02032-4 30739242
Amraee, A. et al. Efficacy of nivolumab as checkpoint inhibitor drug on survival rate of patients with relapsed/refractory classical Hodgkin lymphoma: A meta-analysis of prospective clinical study. Clin. Transl. Oncol. 21(8), 1093–1103 (2019).30739242 10.1007/s12094-018-02032-4
5. Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J. Clin. 2021 71 3 209 249 10.3322/caac.21660 33538338
Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71(3), 209–249 (2021).33538338 10.3322/caac.21660
6. Ansell SM Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management Am. J. Hematol. 2022 97 11 1478 1488 10.1002/ajh.26717 36215668
Ansell, S. M. Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 97(11), 1478–1488 (2022).36215668 10.1002/ajh.26717
7. Ansell SM Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management Am. J. Hematol. 2020 95 8 978 989 10.1002/ajh.25856 32384177
Ansell, S. M. Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 95(8), 978–989 (2020).32384177 10.1002/ajh.25856
8. Chu Y Liu Y Fang X Jiang Y Ding M Ge X The epidemiological patterns of non-Hodgkin lymphoma: Global estimates of disease burden, risk factors, and temporal trends Front. Oncol. 2023 13 1059914 10.3389/fonc.2023.1059914 37333805
Chu, Y. et al. The epidemiological patterns of non-Hodgkin lymphoma: Global estimates of disease burden, risk factors, and temporal trends. Front. Oncol. 13, 1059914 (2023).37333805 10.3389/fonc.2023.1059914
9. Radkiewicz C Bruchfeld JB Weibull CE Jeppesen ML Frederiksen H Lambe M Sex differences in lymphoma incidence and mortality by subtype: A population-based study Am. J. Hematol. 2023 98 1 23 30 10.1002/ajh.26744 36178436
Radkiewicz, C. et al. Sex differences in lymphoma incidence and mortality by subtype: A population-based study. Am. J. Hematol. 98(1), 23–30 (2023).36178436 10.1002/ajh.26744
10. Donzel M Bonjour M Combes J-D Broussais F Sesques P Traverse-Glehen A Lymphomas associated with Epstein-Barr virus infection in 2020: Results from a large, unselected case series in France eClinicalMedicine. 2022 2022 54
Donzel, M. et al. Lymphomas associated with Epstein-Barr virus infection in 2020: Results from a large, unselected case series in France. eClinicalMedicine. 2022, 54 (2022).
11. Navarro JT Moltó J Tapia G Ribera JM Hodgkin lymphoma in people living with HIV Cancers. 2021 13 17 10.3390/cancers13174366
Navarro, J. T., Moltó, J., Tapia, G. & Ribera, J. M. Hodgkin lymphoma in people living with HIV. Cancers. 13, 17 (2021).10.3390/cancers13174366
12. Fallah M Liu X Ji J Försti A Sundquist K Hemminki K Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype Ann. Oncol. 2014 25 7 1397 1404 10.1093/annonc/mdu144 24718892
Fallah, M. et al. Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype. Ann. Oncol. 25(7), 1397–1404 (2014).24718892 10.1093/annonc/mdu144
13. Kamper-Jørgensen M Rostgaard K Glaser SL Zahm SH Cozen W Smedby KE Cigarette smoking and risk of Hodgkin lymphoma and its subtypes: A pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph) Ann. Oncol. 2013 24 9 2245 2255 10.1093/annonc/mdt218 23788758
Kamper-Jørgensen, M. et al. Cigarette smoking and risk of Hodgkin lymphoma and its subtypes: A pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph). Ann. Oncol. 24(9), 2245–2255 (2013).23788758 10.1093/annonc/mdt218
14. Mariotto AB Feuer EJ Howlader N Chen H-S Negoita S Cronin KA Interpreting cancer incidence trends: Challenges due to the COVID-19 pandemic JNCI J. Natl. Cancer Inst. 2023 115 9 1109 1111 10.1093/jnci/djad086 37220901
Mariotto, A. B. et al. Interpreting cancer incidence trends: Challenges due to the COVID-19 pandemic. JNCI J. Natl. Cancer Inst. 115(9), 1109–1111 (2023).37220901 10.1093/jnci/djad086
15. Küçükyurt S Şahin K Yılmaz U Erçalışkan A Özkan Tekin T Ortaboz D Diagnosis and management of classical hodgkin lymphoma during the COVID-19 pandemic Curr. Probl. Cancer 2022 46 6 100913 10.1016/j.currproblcancer.2022.100913 36399974
Küçükyurt, S. et al. Diagnosis and management of classical hodgkin lymphoma during the COVID-19 pandemic. Curr. Probl. Cancer 46(6), 100913 (2022).36399974 10.1016/j.currproblcancer.2022.100913
16. Mburu W Devesa SS Check D Shiels MS Mbulaiteye SM Incidence of Burkitt lymphoma in the United States during 2000 to 2019 Int. J. Cancer 2023 153 6 1182 1191 10.1002/ijc.34618 37278097
Mburu, W., Devesa, S. S., Check, D., Shiels, M. S. & Mbulaiteye, S. M. Incidence of Burkitt lymphoma in the United States during 2000 to 2019. Int. J. Cancer 153(6), 1182–1191 (2023).37278097 10.1002/ijc.34618
17. SEER. About the SEER Program—SEER (2023, accessed 11 Jun 2023). https://seer.cancer.gov/about/overview.html.
18. databse TNCIsS. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER Research Limited-Field Data with Delay-Adjustment, 22 Registries, Malignant Only, Nov 2022 Sub (2000–2020) - Linked To County Attributes—Time Dependent (1990–2021) Income/Rurality, 1969–2021 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2023, based on the November 2022 submission (2022).
19. databse TNCIsS. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER Research Limited-Field Data, 22 Registries, Nov 2022 Sub (2000–2020) —Linked To County Attributes—Time Dependent (1990–2021) Income/Rurality, 1969–2021 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2023, based on the November 2022 submission (2022).
20. SEER. SEER Research Data Agreement. (n.d.). SEER (2023, accessed 11 Jun 2023). https://seer.cancer.gov/data-software/documentation/seerstat/nov2022/seer-dua-nov2022.html.
21. National Cancer Institute. Impact of COVID on the April 2023 SEER Data Release. Available from https://seer.cancer.gov/data/covid-impact-apr2023.html (2023).
22. SEER. Surveillance Research Program, National Cancer Institute SEER*Stat software (seer.cancer.gov/seerstat) version 8.4.1.2 (2023).
23. Clegg LX Feuer EJ Midthune DN Fay MP Hankey BF Impact of reporting delay and reporting error on cancer incidence rates and trends J Natl. Cancer Inst. 2002 94 20 1537 1545 10.1093/jnci/94.20.1537 12381706
Clegg, L. X., Feuer, E. J., Midthune, D. N., Fay, M. P. & Hankey, B. F. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl. Cancer Inst. 94(20), 1537–1545 (2002).12381706 10.1093/jnci/94.20.1537
24. National Cancer Institute. Development of the delay model. Available from https://surveillance.cancer.gov/delay/model.html (2023).
25. Technical Notes—Reporting delay. In SEER Cancer Statistics Review, 1975–2007, National Cancer Institute. Bethesda, MD, based on November 2009 SEER data submission, posted to the SEER website (eds. Altekruse, S. F. et al.) 12–16. [View PDF (PDF)] (2010).
26. Tiwari RC Clegg LX Zou Z Efficient interval estimation for age-adjusted cancer rates Stat. Methods Med. Res. 2006 15 6 547 569 10.1177/0962280206070621 17260923
Tiwari, R. C., Clegg, L. X. & Zou, Z. Efficient interval estimation for age-adjusted cancer rates. Stat. Methods Med. Res. 15(6), 547–569 (2006).17260923 10.1177/0962280206070621
27. Clegg LX Hankey BF Tiwari R Feuer EJ Edwards BK Estimating average annual per cent change in trend analysis Stat. Med. 2009 28 29 3670 3682 10.1002/sim.3733 19856324
Clegg, L. X., Hankey, B. F., Tiwari, R., Feuer, E. J. & Edwards, B. K. Estimating average annual per cent change in trend analysis. Stat. Med. 28(29), 3670–3682 (2009).19856324 10.1002/sim.3733
28. Kim HJ Fay MP Yu B Barrett MJ Feuer EJ Comparability of segmented line regression models Biometrics 2004 60 4 1005 1014 10.1111/j.0006-341X.2004.00256.x 15606421
Kim, H. J., Fay, M. P., Yu, B., Barrett, M. J. & Feuer, E. J. Comparability of segmented line regression models. Biometrics 60(4), 1005–1014 (2004).15606421 10.1111/j.0006-341X.2004.00256.x
29. Kim HJ Chen HS Byrne J Wheeler B Feuer EJ Twenty years since Joinpoint 1.0: Two major enhancements, their justification, and impact Stat. Med. 2022 41 16 3102 3130 10.1002/sim.9407 35522060
Kim, H. J., Chen, H. S., Byrne, J., Wheeler, B. & Feuer, E. J. Twenty years since Joinpoint 1.0: Two major enhancements, their justification, and impact. Stat. Med. 41(16), 3102–3130 (2022).35522060 10.1002/sim.9407
30. Institute, N. C. Joinpoint Regression Program, Version 5.0.2—May 2023; Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute (2023).
31. National Cancer Institute. Weighted BIC (WBIC). Available from https://surveillance.cancer.gov/help/joinpoint/setting-parameters/method-and-parameters-tab/model-selection-method/weighted-bic-wbic (2022).
32. Kim HJ Luo J Chen HS Green D Buckman D Byrne J Improved confidence interval for average annual percent change in trend analysis Stat. Med. 2017 36 19 3059 3074 10.1002/sim.7344 28585245
Kim, H. J. et al. Improved confidence interval for average annual percent change in trend analysis. Stat. Med. 36(19), 3059–3074 (2017).28585245 10.1002/sim.7344
33. Glaser SL Clarke CA Keegan TH Chang ET Weisenburger DD Time trends in rates of Hodgkin lymphoma histologic subtypes: True incidence changes or evolving diagnostic practice? Cancer Epidemiol. Biomark. Prevent. 2015 24 10 1474 1488 10.1158/1055-9965.EPI-15-0281
Glaser, S. L., Clarke, C. A., Keegan, T. H., Chang, E. T. & Weisenburger, D. D. Time trends in rates of Hodgkin lymphoma histologic subtypes: True incidence changes or evolving diagnostic practice?. Cancer Epidemiol. Biomark. Prevent. 24(10), 1474–1488 (2015).10.1158/1055-9965.EPI-15-0281
34. Evens AM Antillón M Aschebrook-Kilfoy B Chiu BCH Racial disparities in Hodgkin's lymphoma: A comprehensive population-based analysis Ann. Oncol. 2012 23 8 2128 2137 10.1093/annonc/mdr578 22241896
Evens, A. M., Antillón, M., Aschebrook-Kilfoy, B. & Chiu, B. C. H. Racial disparities in Hodgkin’s lymphoma: A comprehensive population-based analysis. Ann. Oncol. 23(8), 2128–2137 (2012).22241896 10.1093/annonc/mdr578
35. Shenoy P Maggioncalda A Malik N Flowers CR Incidence patterns and outcomes for Hodgkin lymphoma patients in the United States Adv. Hematol. 2011 2011 1 11 10.1155/2011/725219
Shenoy, P., Maggioncalda, A., Malik, N. & Flowers, C. R. Incidence patterns and outcomes for Hodgkin lymphoma patients in the United States. Adv. Hematol. 2011, 1–11 (2011).10.1155/2011/725219
36. Shen J Luo M Liu L Chen Q-Y Tang L-Q Mai H-Q Incidence and trend of Epstein-Barr virus-related cancer: A surveillance, epidemiology, and end results program based study Wolters Kluwer Health 2021 39 10575
Shen, J. et al. Incidence and trend of Epstein-Barr virus-related cancer: A surveillance, epidemiology, and end results program based study. Wolters Kluwer Health 39, 10575 (2021).
37. Khanali J Kolahi A-A National and subnational cancer incidence for 22 cancer groups, 2000 to 2016: A study based on cancer registration data of Iran J. Cancer Epidemiol. 2021 2021 1 6676666 34335766
Khanali, J. & Kolahi, A.-A. National and subnational cancer incidence for 22 cancer groups, 2000 to 2016: A study based on cancer registration data of Iran. J. Cancer Epidemiol. 2021(1), 6676666 (2021).34335766
38. Hadaegh F Asgari S Hashemi P Baghbani-Oskouei A Eskandari F Azizi F All-cancer incidence in Tehranian adults: More than a decade of follow-up—results from the Tehran Lipid and Glucose Study Public Health. 2020 181 189 195 10.1016/j.puhe.2020.01.003 32088600
Hadaegh, F. et al. All-cancer incidence in Tehranian adults: More than a decade of follow-up—results from the Tehran Lipid and Glucose Study. Public Health. 181, 189–195 (2020).32088600 10.1016/j.puhe.2020.01.003
39. Farzadfar F Naghavi M Sepanlou SG Saeedi Moghaddam S Dangel WJ Davis Weaver N Health system performance in Iran: A systematic analysis for the Global Burden of Disease Study 2019 The Lancet. 2022 399 10335 1625 1645 10.1016/S0140-6736(21)02751-3
Farzadfar, F. et al. Health system performance in Iran: A systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 399(10335), 1625–1645 (2022).10.1016/S0140-6736(21)02751-3
40. Keykhosravi A Neamatshahi M Navipour E Barabadi Z Neamatshahi M Incidence prevalence and associated risk factors for leukemia and lyphoma occurrence in Iran: A systematic review and meta analysis Int. J. Med. Rev. 2021 8 2 57 64
Keykhosravi, A., Neamatshahi, M., Navipour, E., Barabadi, Z. & Neamatshahi, M. Incidence prevalence and associated risk factors for leukemia and lyphoma occurrence in Iran: A systematic review and meta analysis. Int. J. Med. Rev. 8(2), 57–64 (2021).
41. Cornelius ME Loretan CG Jamal A Davis Lynn BC Mayer M Alcantara IC Tobacco product use among adults—United States, 2021 MMWR Morb. Mortal Wkly. Rep. 2023 72 18 475 483 10.15585/mmwr.mm7218a1 37141154
Cornelius, M. E. et al. Tobacco product use among adults—United States, 2021. MMWR Morb. Mortal Wkly. Rep. 72(18), 475–483 (2023).37141154 10.15585/mmwr.mm7218a1
42. Ng M Fleming T Robinson M Thomson B Graetz N Margono C Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: A systematic analysis for the Global Burden of Disease Study 2013 The lancet. 2014 384 9945 766 781 10.1016/S0140-6736(14)60460-8
Ng, M. et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: A systematic analysis for the Global Burden of Disease Study 2013. The lancet. 384(9945), 766–781 (2014).10.1016/S0140-6736(14)60460-8
43. Collaborators GO Health effects of overweight and obesity in 195 countries over 25 years N. Engl. J. Med. 2017 377 1 13 27 10.1056/NEJMoa1614362 28604169
Collaborators, G. O. Health effects of overweight and obesity in 195 countries over 25 years. N. Engl. J. Med. 377(1), 13–27 (2017).28604169 10.1056/NEJMoa1614362
44. Wong MCS Huang J Wang J Chan PSF Lok V Chen X Global, regional and time-trend prevalence of central obesity: A systematic review and meta-analysis of 132 million subjects Eur. J. Epidemiol. 2020 35 7 673 683 10.1007/s10654-020-00650-3 32448986
Wong, M. C. S. et al. Global, regional and time-trend prevalence of central obesity: A systematic review and meta-analysis of 132 million subjects. Eur. J. Epidemiol. 35(7), 673–683 (2020).32448986 10.1007/s10654-020-00650-3
45. Glaser SL Hsu JL Hodgkin's disease in Asians: Incidence patterns and risk factors in population-based data Leuk. Res. 2002 26 3 261 269 10.1016/S0145-2126(01)00126-6 11792415
Glaser, S. L. & Hsu, J. L. Hodgkin’s disease in Asians: Incidence patterns and risk factors in population-based data. Leuk. Res. 26(3), 261–269 (2002).11792415 10.1016/S0145-2126(01)00126-6
46. Hjalgrim H Engels EA Infectious aetiology of Hodgkin and non-Hodgkin lymphomas: A review of the epidemiological evidence J. Intern. Med. 2008 264 6 537 548 10.1111/j.1365-2796.2008.02031.x 19017178
Hjalgrim, H. & Engels, E. A. Infectious aetiology of Hodgkin and non-Hodgkin lymphomas: A review of the epidemiological evidence. J. Intern. Med. 264(6), 537–548 (2008).19017178 10.1111/j.1365-2796.2008.02031.x
47. Alexander FE Ricketts TJ McKinney PA Cartwright RA Community lifestyle characteristics and incidence of Hodgkin's disease in young people Int. J. Cancer. 1991 48 1 10 14 10.1002/ijc.2910480103 2019450
Alexander, F. E., Ricketts, T. J., McKinney, P. A. & Cartwright, R. A. Community lifestyle characteristics and incidence of Hodgkin’s disease in young people. Int. J. Cancer. 48(1), 10–14 (1991).2019450 10.1002/ijc.2910480103
48. Gutensohn N Cole P Childhood social environment and Hodgkin's disease N. Engl. J. Med. 1981 304 3 135 140 10.1056/NEJM198101153040302 6255329
Gutensohn, N. & Cole, P. Childhood social environment and Hodgkin’s disease. N. Engl. J. Med. 304(3), 135–140 (1981).6255329 10.1056/NEJM198101153040302
49. Jones SJ Stroshein S Williams AM Liu D Spinelli JJ Connors JM Birth order, sibship size, childhood environment and immune-related disorders, and risk of lymphoma in lymphoid cancer families Cancer Epidemiol. Biomark. Prevent. 2020 29 6 1168 1178 10.1158/1055-9965.EPI-19-1204
Jones, S. J. et al. Birth order, sibship size, childhood environment and immune-related disorders, and risk of lymphoma in lymphoid cancer families. Cancer Epidemiol. Biomark. Prevent. 29(6), 1168–1178 (2020).10.1158/1055-9965.EPI-19-1204
50. Chang ET Zheng T Weir EG Borowitz M Mann RB Spiegelman D Childhood social environment and Hodgkin's lymphoma: New findings from a population-based case-control study Cancer Epidemiol. Biomark. Prev. 2004 13 8 1361 1370 10.1158/1055-9965.1361.13.8
Chang, E. T. et al. Childhood social environment and Hodgkin’s lymphoma: New findings from a population-based case-control study. Cancer Epidemiol. Biomark. Prev. 13(8), 1361–1370 (2004).10.1158/1055-9965.1361.13.8
51. Zhu C Bassig BA Shi K Boyle P Guo H Zheng T Different time trends by gender for the incidence of Hodgkin’s lymphoma among young adults in the USA: A birth cohort phenomenon Cancer Causes Control. 2014 25 8 923 931 10.1007/s10552-014-0391-5 24879043
Zhu, C. et al. Different time trends by gender for the incidence of Hodgkin’s lymphoma among young adults in the USA: A birth cohort phenomenon. Cancer Causes Control. 25(8), 923–931 (2014).24879043 10.1007/s10552-014-0391-5
52. Keykhaei M Masinaei M Mohammadi E Azadnajafabad S Rezaei N Saeedi Moghaddam S A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017 Exp. Hematol. Oncol. 2021 10 1 11 10.1186/s40164-021-00198-2 33557940
Keykhaei, M. et al. A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017. Exp. Hematol. Oncol. 10(1), 11 (2021).33557940 10.1186/s40164-021-00198-2
53. Juntikka T Malila N Ylöstalo T Merikivi M Jyrkkiö S Epidemiology of classic and nodular lymphocyte predominant hodgkin lymphoma in Finland in 1996–2015 Acta Oncol. 2020 59 5 574 581 10.1080/0284186X.2019.1711166 31910680
Juntikka, T., Malila, N., Ylöstalo, T., Merikivi, M. & Jyrkkiö, S. Epidemiology of classic and nodular lymphocyte predominant hodgkin lymphoma in Finland in 1996–2015. Acta Oncol. 59(5), 574–581 (2020).31910680 10.1080/0284186X.2019.1711166
54. Ye X Mahmud S Skrabek P Lix L Johnston JB Long-term time trends in incidence, survival and mortality of lymphomas by subtype among adults in Manitoba, Canada: A population-based study using cancer registry data BMJ Open. 2017 7 7 e015106 10.1136/bmjopen-2016-015106 28716788
Ye, X., Mahmud, S., Skrabek, P., Lix, L. & Johnston, J. B. Long-term time trends in incidence, survival and mortality of lymphomas by subtype among adults in Manitoba, Canada: A population-based study using cancer registry data. BMJ Open. 7(7), e015106 (2017).28716788 10.1136/bmjopen-2016-015106
55. Solans M Serra L Renart G Osca-Gelis G Comas R Vilardell L Incidence and survival of Hodgkin lymphoma patients in Girona (Spain) over three decades: A population-based study Eur. J. Cancer Prev. 2017 2017 26
Solans, M. et al. Incidence and survival of Hodgkin lymphoma patients in Girona (Spain) over three decades: A population-based study. Eur. J. Cancer Prev. 2017, 26 (2017).
56. Clavel J Steliarova-Foucher E Berger C Danon S Valerianova Z Hodgkin’s disease incidence and survival in European children and adolescents (1978–1997): Report from the Automated Cancer Information System project Eur. J. Cancer 2006 42 13 2037 2049 10.1016/j.ejca.2006.05.012 16919769
Clavel, J., Steliarova-Foucher, E., Berger, C., Danon, S. & Valerianova, Z. Hodgkin’s disease incidence and survival in European children and adolescents (1978–1997): Report from the Automated Cancer Information System project. Eur. J. Cancer 42(13), 2037–2049 (2006).16919769 10.1016/j.ejca.2006.05.012
57. Hjalgrim H Askling J Pukkala E Hansen S Munksgaard L Frisch M Incidence of Hodgkin's disease in Nordic countries Lancet. 2001 358 9278 297 298 10.1016/S0140-6736(01)05498-8 11498219
Hjalgrim, H. et al. Incidence of Hodgkin’s disease in Nordic countries. Lancet. 358(9278), 297–298 (2001).11498219 10.1016/S0140-6736(01)05498-8
58. Morton LM Wang SS Devesa SS Hartge P Weisenburger DD Linet MS Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001 Blood. 2006 107 1 265 276 10.1182/blood-2005-06-2508 16150940
Morton, L. M. et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 107(1), 265–276 (2006).16150940 10.1182/blood-2005-06-2508
59. van Leeuwen MT Turner JJ Joske DJ Falster MO Srasuebkul P Meagher NS Lymphoid neoplasm incidence by WHO subtype in Australia 1982–2006 Int. J. Cancer 2014 135 9 2146 2156 10.1002/ijc.28849 24639369
van Leeuwen, M. T. et al. Lymphoid neoplasm incidence by WHO subtype in Australia 1982–2006. Int. J. Cancer 135(9), 2146–2156 (2014).24639369 10.1002/ijc.28849
60. Das DK Francis IM Sharma PN Sathar SA John B George SS Hodgkin's lymphoma: Diagnostic difficulties in fine-needle aspiration cytology Diagn. Cytopathol. 2009 37 8 564 573 10.1002/dc.21064 19373880
Das, D. K. et al. Hodgkin’s lymphoma: Diagnostic difficulties in fine-needle aspiration cytology. Diagn. Cytopathol. 37(8), 564–573 (2009).19373880 10.1002/dc.21064
61. Wilkins BS Pitfalls in lymphoma pathology: Avoiding errors in diagnosis of lymphoid tissues J. Clin. Pathol. 2011 64 6 466 476 10.1136/jcp.2010.080846 21325143
Wilkins, B. S. Pitfalls in lymphoma pathology: Avoiding errors in diagnosis of lymphoid tissues. J. Clin. Pathol. 64(6), 466–476 (2011).21325143 10.1136/jcp.2010.080846
62. Devilard E Bertucci F Trempat P Bouabdallah R Loriod B Giaconia A Gene expression profiling defines molecular subtypes of classical Hodgkin's disease Oncogene. 2002 21 19 3095 3102 10.1038/sj.onc.1205418 12082542
Devilard, E. et al. Gene expression profiling defines molecular subtypes of classical Hodgkin’s disease. Oncogene. 21(19), 3095–3102 (2002).12082542 10.1038/sj.onc.1205418
63. Tiacci E Döring C Brune V van Noesel CJ Klapper W Mechtersheimer G Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma Blood. 2012 120 23 4609 4620 10.1182/blood-2012-05-428896 22955914
Tiacci, E. et al. Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood. 120(23), 4609–4620 (2012).22955914 10.1182/blood-2012-05-428896
64. Qadir MI Ahmed B Hussain N Efficacy and nuances of precision molecular engineering for Hodgkin’s disease to a gene therapeutic approach Crit. Rev. Immunol. 2024 2024 44
Qadir, M. I., Ahmed, B. & Hussain, N. Efficacy and nuances of precision molecular engineering for Hodgkin’s disease to a gene therapeutic approach. Crit. Rev. Immunol. 2024, 44 (2024).
65. Olszewski AJ Shrestha R Castillo JJ Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: Analysis of the National Cancer Data Base J. Clin. Oncol. 2015 33 6 625 633 10.1200/JCO.2014.58.7543 25584010
Olszewski, A. J., Shrestha, R. & Castillo, J. J. Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: Analysis of the National Cancer Data Base. J. Clin. Oncol. 33(6), 625–633 (2015).25584010 10.1200/JCO.2014.58.7543
66. Ali S Olszewski AJ Disparate survival and risk of secondary non-Hodgkin lymphoma in histologic subtypes of Hodgkin lymphoma: A population-based study Leuk. Lymphoma 2014 55 7 1570 1577 10.3109/10428194.2013.847938 24067135
Ali, S. & Olszewski, A. J. Disparate survival and risk of secondary non-Hodgkin lymphoma in histologic subtypes of Hodgkin lymphoma: A population-based study. Leuk. Lymphoma 55(7), 1570–1577 (2014).24067135 10.3109/10428194.2013.847938
67. Grulich AE Van Leeuwen MT Falster MO Vajdic CM Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis The Lancet. 2007 370 9581 59 67 10.1016/S0140-6736(07)61050-2
Grulich, A. E., Van Leeuwen, M. T., Falster, M. O. & Vajdic, C. M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. The Lancet. 370(9581), 59–67 (2007).10.1016/S0140-6736(07)61050-2
68. Shiels MS Koritzinsky EH Clarke CA Suneja G Morton LM Engels EA Prevalence of HIV Infection among US Hodgkin lymphoma cases Cancer Epidemiol. Biomark. Prevent. 2014 23 2 274 281 10.1158/1055-9965.EPI-13-0865
Shiels, M. S. et al. Prevalence of HIV Infection among US Hodgkin lymphoma cases. Cancer Epidemiol. Biomark. Prevent. 23(2), 274–281 (2014).10.1158/1055-9965.EPI-13-0865
69. Glaser S Clarke C Chang E Yang J Gomez S Keegan T Hodgkin lymphoma incidence in California Hispanics: Influence of nativity and tumor Epstein-Barr virus Cancer Causes Control. 2014 25 709 725 10.1007/s10552-014-0374-6 24722952
Glaser, S. et al. Hodgkin lymphoma incidence in California Hispanics: Influence of nativity and tumor Epstein-Barr virus. Cancer Causes Control. 25, 709–725 (2014).24722952 10.1007/s10552-014-0374-6
70. Chihara D Ito H Matsuda T Shibata A Katsumi A Nakamura S Differences in incidence and trends of haematological malignancies in J apan and the U nited S tates Br. J. Haematol. 2014 164 4 536 545 10.1111/bjh.12659 24245986
Chihara, D. et al. Differences in incidence and trends of haematological malignancies in J apan and the U nited S tates. Br. J. Haematol. 164(4), 536–545 (2014).24245986 10.1111/bjh.12659
71. Matsuoka S Nagashima M Sadamasu K Mori H Kawahata T Zaitsu S Estimating HIV-1 incidence in Japan from the proportion of recent infections Prevent. Med. Rep. 2019 16 100994 10.1016/j.pmedr.2019.100994
Matsuoka, S. et al. Estimating HIV-1 incidence in Japan from the proportion of recent infections. Prevent. Med. Rep. 16, 100994 (2019).10.1016/j.pmedr.2019.100994
72. McNally RJ Alston RD Cairns DP Eden OB Birch JM Geographical and ecological analyses of childhood acute leukaemias and lymphomas in north-west England Br. J. Haematol. 2003 123 1 60 65 10.1046/j.1365-2141.2003.04558.x 14510943
McNally, R. J., Alston, R. D., Cairns, D. P., Eden, O. B. & Birch, J. M. Geographical and ecological analyses of childhood acute leukaemias and lymphomas in north-west England. Br. J. Haematol. 123(1), 60–65 (2003).14510943 10.1046/j.1365-2141.2003.04558.x
73. Reitsma MB Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: A systematic analysis from the Global Burden of Disease Study 2019 Lancet. 2021 397 10292 2337 2360 10.1016/S0140-6736(21)01169-7 34051883
Reitsma, M. B. et al. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: A systematic analysis from the Global Burden of Disease Study 2019. Lancet. 397(10292), 2337–2360 (2021).34051883 10.1016/S0140-6736(21)01169-7
74. Balfour HH Jr Meirhaeghe MR Stancari AL Geris JM Condon LM Cederberg LE Declining Epstein-Barr Virus antibody prevalence in college freshmen strengthens the rationale for a prophylactic EBV vaccine Vaccines (Basel). 2022 10 9
Balfour, H. H. Jr. et al. Declining Epstein-Barr Virus antibody prevalence in college freshmen strengthens the rationale for a prophylactic EBV vaccine. Vaccines (Basel). 10, 9 (2022).
75. Shen J Luo M Liu L Chen Q-Y Tang L-Q Mai H-Q Incidence and trend of Epstein-Barr virus-related cancer: A surveillance, epidemiology, and end results program based study J. Clin. Oncol. 2021 39 15 10575 10.1200/JCO.2021.39.15_suppl.10575
Shen, J. et al. Incidence and trend of Epstein-Barr virus-related cancer: A surveillance, epidemiology, and end results program based study. J. Clin. Oncol. 39(15), 10575 (2021).10.1200/JCO.2021.39.15_suppl.10575
76. Strobbe L Valke LL Diets IJ van den Brand M Aben K Raemaekers JM A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma Ann. Hematol. 2016 95 3 417 423 10.1007/s00277-015-2578-6 26732883
Strobbe, L. et al. A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma. Ann. Hematol. 95(3), 417–423 (2016).26732883 10.1007/s00277-015-2578-6
77. Rucinska M Nawrocki S COVID-19 pandemic: Impact on cancer patients Int. J. Environ. Res. Public Health. 2022 19 19 10.3390/ijerph191912470
Rucinska, M. & Nawrocki, S. COVID-19 pandemic: Impact on cancer patients. Int. J. Environ. Res. Public Health. 19, 19 (2022).10.3390/ijerph191912470
78. Boettcher AN Hammoud DA Weinberg JB Agarwal P Mendiratta-Lala M Luker GD Cancer imaging and patient care during the COVID-19 pandemic Radiol. Imaging Cancer. 2020 2 6 e200058 10.1148/rycan.2020200058 33778750
Boettcher, A. N. et al. Cancer imaging and patient care during the COVID-19 pandemic. Radiol. Imaging Cancer. 2(6), e200058 (2020).33778750 10.1148/rycan.2020200058
79. Koczkodaj P Kamiński MF Ciuba A Didkowska J Cancer screening coverage in Poland–from bad to better to the worst during the SARS-CoV-2 pandemic Arch. Med. Sci. 2021 17 4 1132 1133 10.5114/aoms/134239 34336043
Koczkodaj, P., Kamiński, M. F., Ciuba, A. & Didkowska, J. Cancer screening coverage in Poland–from bad to better to the worst during the SARS-CoV-2 pandemic. Arch. Med. Sci. 17(4), 1132–1133 (2021).34336043 10.5114/aoms/134239
80. Cantini L Mentrasti G Russo GL Signorelli D Pasello G Rijavec E Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): Fewer cases and higher stages from a real-world scenario ESMO Open. 2022 7 2 100406 10.1016/j.esmoop.2022.100406 35219245
Cantini, L. et al. Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): Fewer cases and higher stages from a real-world scenario. ESMO Open. 7(2), 100406 (2022).35219245 10.1016/j.esmoop.2022.100406
81. Muka T Li JJ Farahani SJ Ioannidis JP An umbrella review of systematic reviews on the impact of the COVID-19 pandemic on cancer prevention and management, and patient needs Elife 2023 2023 12
Muka, T., Li, J. J., Farahani, S. J. & Ioannidis, J. P. An umbrella review of systematic reviews on the impact of the COVID-19 pandemic on cancer prevention and management, and patient needs. Elife 2023, 12 (2023).
82. Mousavi SE Ilaghi M Aslani A Yekta Z Nejadghaderi SA A population-based study on incidence trends of myeloma in the United States over 2000–2020 Sci. Rep. 2023 13 1 20705 10.1038/s41598-023-47906-y 38001246
Mousavi, S. E., Ilaghi, M., Aslani, A., Yekta, Z. & Nejadghaderi, S. A. A population-based study on incidence trends of myeloma in the United States over 2000–2020. Sci. Rep. 13(1), 20705 (2023).38001246 10.1038/s41598-023-47906-y
83. Romito F Dellino M Loseto G Opinto G Silvestris E Cormio C Psychological distress in outpatients with lymphoma during the COVID-19 pandemic Front. Oncol. 2020 10 1270 10.3389/fonc.2020.01270 32754447
Romito, F. et al. Psychological distress in outpatients with lymphoma during the COVID-19 pandemic. Front. Oncol. 10, 1270 (2020).32754447 10.3389/fonc.2020.01270
84. ElGohary GM Hashmi S Styczynski J Kharfan-Dabaja MA Alblooshi RM de la Cámara R The risk and prognosis of COVID-19 infection in cancer patients: A systematic review and meta-analysis Hematol. Oncol. Stem Cell Therapy. 2020 2020 89
ElGohary, G. M. et al. The risk and prognosis of COVID-19 infection in cancer patients: A systematic review and meta-analysis. Hematol. Oncol. Stem Cell Therapy. 2020, 89 (2020).
85. Patt D Gordan L Diaz M Okon T Grady L Harmison M Impact of COVID-19 on cancer care: How the pandemic is delaying cancer diagnosis and treatment for American seniors JCO Clin. Cancer Inf. 2020 4 1059 1071 10.1200/CCI.20.00134
Patt, D. et al. Impact of COVID-19 on cancer care: How the pandemic is delaying cancer diagnosis and treatment for American seniors. JCO Clin. Cancer Inf. 4, 1059–1071 (2020).10.1200/CCI.20.00134
